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Supplement introduction
Welcome to the fourth Supplement to the Health Technology Assessment journal series. 
The series is now over 10 years old and has 
published more than 400 titles, covering a wide 
range of health technologies in a diverse set of 
applications. In general, the series publishes each 
technology assessment as a separate issue within 
each annual volume. 
The Supplements depart from that format by 
containing a series of shorter articles. These are all 
products from a ‘call-off contract’, which the HTA 
programme holds with a range of academic centres 
around the UK, at the universities of Aberdeen, 
Birmingham, Exeter, Liverpool, Sheffield, 
Southampton and York. These centres are retained 
to provide a highly responsive resource, which 
meets the needs of national policy makers, notably 
the National Institute for Health and Clinical 
Excellence (NICE).
Until recently, these HTA Technology Assessment 
Review (TAR) centres provided academic input to 
policy making through independent analyses of 
the impact and value of health technologies. As 
many readers will be aware, the perception that 
the advice NICE provides to the NHS could be 
made more timely has led to the development of 
the ‘Single Technology Appraisal’ process. In this 
approach, manufacturers of technologies, which 
are, in general, pharmaceuticals close to the time 
of launch, submit a dossier of evidence aiming to 
demonstrate effectiveness and cost-effectiveness. 
The independent academic input to NICE’s 
process, which continues to be supported by the 
TAR centres around the UK under contract to the 
HTA programme, is to scrutinise, critique and 
explore this dossier of evidence.
The papers included in this Supplement report 
on this HTA programme funded work, and we 
hope that the summaries of the work carried out 
to inform the development of NICE guidance for 
these technologies will be of interest and value to 
readers. 
Further details of each of the NICE Appraisals are 
available on the NICE website (www. nice.org.uk) 
and we welcome comments on the summaries via 
the HTA website (www.hta.ac.uk/correspond/).
Prof. Tom Walley 
Director, NIHR HTA programme 
Editor-In-Chief, Health Technology Assessment
Prof. Ken Stein 
Chair, Editorial Board, Health Technology Assessment
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of cetuximab 
for the first-line treatment of metastatic colorectal 
cancer (mCRC), in accordance with the licensed 
indication, based upon the manufacturer’s 
submission to the National Institute for Health and 
Clinical Excellence (NICE) as part of the single 
technology appraisal process. The ERG project ran 
between 22 January 2008 and 4 November 2008. 
The clinical evidence came from two unpublished 
randomised controlled trials (RCTs) of cetuximab 
plus chemotherapy versus chemotherapy alone 
in the first-line treatment of mCRC. A third 
RCT submitted later compared cetuximab with 
irinotecan in combination with 5-fluorouracil 
(5-FU) and folinic acid (FA) and cetuximab with 
oxaliplatin in combination with 5-FU and FA in 
patients with mCRC with liver metastases only. No 
published economic evaluations of cetuximab for 
first-line chemotherapy in mCRC were identified 
in the submission. A de novo model examined the 
cost-effectiveness of cetuximab in patients with 
mCRC that was epidermal growth factor receptor 
positive, k-ras wild type and with liver metastases. 
The main source of clinical effectiveness evidence 
came from the first two RCTs which provided 
follow up information for 1–2 years. Secondary 
information was used to estimate survival for 
a further 22 years. The model focused on the 
patients for whom the treatment had been licensed. 
This limited the applicability of the model to 
the NHS setting in which patients would be a 
mixture of k-ras wild type and mutations and also a 
mixture of patients with liver metastases and other 
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metastases. The difference in progression-free 
survival for the two trials was between 0.5 to 1.2 
months over a 7–10 month period. Eight months’ 
treatment with cetuximab, given as an initial 
loading dose and then weekly until progression, 
would cost around £22,932 for an average man 
and £18,427 for an average woman. It is uncertain 
whether this constitutes good value for money. 
The guidance issued by NICE on 25 September 
2008 stated that cetuximab was not recommended 
for the first-line treatment of mCRC and people 
currently receiving cetuximab for the first-line 
treatment of mCRC should have the option to 
continue treatment until they and their clinicians 
consider it appropriate to stop.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, where most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG); an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
entitled ‘Cetuximab for the first-line treatment of 
metastatic colorectal cancer (mCRC)’.2
Description of the underlying 
health problem
Colorectal cancer is a malignant neoplasm 
arising from the lining (mucosa) of the large 
intestine (colon and rectum). Colorectal cancer 
is the third most common cancer in the UK, with 
approximately 30,000 new cases registered in 
England and Wales in 2002. This represents 12% 
of all new cancer cases in women and 14% of all 
new cancer cases in men. In people between the 
ages of 45 and 49 years, the incidence is 20 per 
100,000. Amongst those over 75 years of age, the 
incidence is over 300 per 100,000 for men and 200 
per 100,000 per year for women. The median age 
of patients at diagnosis is over 70 years.
In mCRC the tumour has spread beyond the 
confines of the locoregional lymph nodes to other 
parts of the body. This is described as stage IV of 
the American Joint Committee on Cancer tumour 
node metastases system, or stage D of Dukes’ 
classification. Estimates of people presenting with 
mCRC range from 20% to 55% of new cases. In 
addition, out of patients who have undergone 
surgery for early stage colorectal cancer with 
apparently complete excision, approximately 
50% will eventually develop advanced disease and 
distant metastases (typically presenting within  
2 years of initial diagnosis). The 5-year survival  
rate for metastatic colorectal disease is 12%.
The management of mCRC is mainly palliative 
and involves a combination of specialist treatments 
(such as palliative surgery, chemotherapy and 
radiation), symptom control and psychosocial 
support. However, approximately 20% of patients 
with mCRC present with potentially resectable liver 
metastases. In addition, estimates suggest that for 
between 10% and 50% of patients, chemotherapy 
may render unresectable liver metastases operable. 
The resection of metastases can result in longer 
term survival for a proportion of patients. Flow of 
patients and approximate percentages can be seen 
FIGURE 1 (Opposite) Treatment algorithm for people with colorectal cancer in England and Wales. a, Office for National Statistics,4 
Welsh Cancer Intelligence and Surveillance Unit5; b, South West Cancer Intelligence Service13; c, Seymour M, Leeds Teaching Hospitals 
NHS Trust, personal communication: between 33% and 60% of people with Dukes’ B cancer receive adjuvant chemotherapy (this 
study assumed the lower estimate); d, Seymour M, personal communication: more than 85% receive adjuvant chemotherapy; e, 
Seymour M, personal communication: 20–25% of patients with Dukes’ B will relapse; f, estimated 40% relative risk increase of relapse 
for surgery alone versus chemotherapy, from pooled multicentre trial.39 Relative risk increase applied to 5-year disease-free survival 
estimates from X-ACT trial;40 g, 5-year disease-free survival estimates from X-ACT trial;40 h, Maughan T, Velindre Hospital, Cardiff, 
personal communication; i, data from case series41 suggest up to 20% may be resectable, although this is an aggressive stance; a 
maximum of 15% of patients are suitable; Maughan T, personal communication; j, Poston G, Royal Liverpool University Hospital, 
personal communication; k, data from case series41; l, Seymour M, personal communication: 85–90% of advanced patients receive 
chemotherapy42; m, preliminary data from FOCUS trial42; n, Glynne Jones R, Watford and Barnet General Hospitals, London, personal 
communication: only 3–5% patients would receive third-line therapy. [Note: the numbers in the text above refer to references in Hind 
et al.,3 boxes with subscript letters c and d have error where the 33% and the 85% boxes (right-hand side of each pair) should read 
adjuvant chemotherapy whereas the left-hand side boxes should read no adjuvant chemotherapy (Steven N, University of Birmingham, 
July 2008, personal communication).] Figure reproduced with permission from Hind et al. Health Technol Assess 2008; 12(15).
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in Figure 1, reproduced with permission from a 
recent HTA report.3
Current guidance from NICE recommends 
oxaliplatin in combination with 5-fluorouracil (5-
FU) and folinic acid (FA) (FOLFOX) and irinotecan 
in combination with 5-FU/FA (FOLFIRI) as first-
line treatment options (technology appraisal 
934). The oral analogues of 5-FU capecitabine 
and tegafur with uracil are also recommended 
as treatment options (technology appraisal 
615). Bevacizumab as a first-line treatment and 
cetuximab as a treatment following the failure of 
an irinotecan-including chemotherapy regimen 
are not recommended as treatment options 
(technology appraisal 1186).
Scope of the evidence 
review group report
The purpose of the ERG report is to comment 
on the validity of the manufacturer’s submission 
on the technology of interest. The scope for this 
submission and hence the scope for the ERG report 
was:
To appraise the clinical and cost effectiveness 
of cetuximab within its licensed indication for 
the first line treatment of metastatic colorectal 
cancer.7
The relevant Commitee for Medicinal Products 
for Human Use (CHMP) positive opinion for 
cetuximab (Erbitux) was:
Erbitux is indicated for the treatment of patients 
with epidermal growth factor receptor (EGFR) 
expressing k-ras (k-ras is the gene that encodes for 
KRAS, a protein that acts in cellular proliferation 
and transformation) wild-type mCRC:
• in combination with chemotherapy
• as a single agent in patients who have failed 
oxaliplatin- and irinotecan-based therapy and 
who are intolerant to irinotecan.
Methods
The ERG report comprised a critical review 
of the evidence for the clinical evidence and 
cost-effectiveness of cetuximab based upon the 
manufacturer’s submission to NICE as part of the 
STA process. Specific steps undertaken by the ERG 
included:
• discussion of the nature of the problem with a 
clinical expert
• reanalysis of the nature of the clinical question
• rerunning searches indicated to have been 
carried out to inform the manufacturer’s 
submission
• extending searches, particularly for ongoing 
trials
• formal critical appraisal of the systematic 
review of clinical effectiveness and cost-
effectiveness data underpinning the 
manufacturer’s submission
• reappraisal and checking of effectiveness and 
safety data from unpublished trial reports
• formal critical appraisal of the de novo 
economic model
• checking the consistency of the effectiveness 
estimates emerging from the trials with the 
parameters used in the economic model
• rerunning the model for a 5-year time horizon 
instead of the original 23-year time horizon as 
submitted by the manufacturer
• evaluating the evidence regarding clinical 
sensitivity and specificity of k-ras and EGFR 
tests
• evaluating a best-case scenario analysis of the 
model submitted as a response to clarifications
• evaluating a separate budget impact model 
submitted by the manufacturer
• evaluation of additional material from a third 
randomised controlled trial (RCT) and a 
reworked economic model between the first 
and second appraisal committee meetings.
The work was carried out between 22 January 
2008 and 4 November 2008 (report submitted 22 
July 2008). Members of the ERG team attended 
and advised the meetings of the NICE Appraisal 
Committee in which this guidance was discussed, 
on 3 September 2008 and 4 November 2008.
Results
Summary of submitted 
clinical evidence
The originally submitted clinical effectiveness 
consists of two unpublished RCTs of cetuximab 
plus chemotherapy versus chemotherapy alone in 
the first-line treatment of mCRC. The CRYSTAL 
trial enrolled 1217 patients with EGFR expressing 
mCRC, and the combination chemotherapy was 
FOLFIRI. The OPUS trial enrolled 337 patients 
with previously untreated EGFR expressing mCRC 
that was not resectable with curative intent, and the 
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chemotherapy used was FOLFOX4. Full follow-up 
was for [commercial-in-confidence data removed] 
months in the CRYSTAL trial when [commercial-
in-confidence data removed] in both arms of the 
trial either had died or was lost to follow up. Full 
follow-up in the CRYSTAL trial, k-ras wild-type 
subgroup was given at 16 months, and there were 
six patients remaining in the intervention arm 
and three in the control arm. For the OPUS trial, 
full trial results for progression-free survival and 
overall survival were not found in the submission 
or the trial report, so are not presented here. For 
the OPUS trial k-ras subgroup, the equivalent 
numbers at 12-month follow-up were four patients 
in the intervention arm and two in the control 
arm. The difference in median progression-free 
survival in the CRYSTAL trial, for the k-ras wild-
type subgroup, was 1.2 months (9.9 months versus 
8.7 months) and for the OPUS trial k-ras wild-type 
subgroup was 0.5 months (7.7 months versus 7.2 
months). Survival curves for these two trials are 
presented in Figure 2. A third RCT, the CELIM 
trial, was submitted for assessment between the first 
and second appraisal committee meetings.5 This 
compared cetuximab with FOLFIRI and cetuximab 
with FOLFOX in 111 patients with mCRC with 
liver metastases only. Interim results only were 
presented.
Table 1 shows a comparison of the NICE scope, the 
CHMP positive opinion, the submission and the 
two originally submitted trials.
TABLE 1 Comparison of NICE scope, CHMP positive opinion, submission and RCTs
NICE scope CHMP Submission Trials 
Patients Untreated mCRC, first-
line palliative 
EGFR expressing k-ras 
wild type mCRC
Untreated EGFR 
expressing k-ras wild 
type mCRC 
Previously untreated 
mCRC 
Metastases Untreated, any location Any location In model – metastases 
only in liver
Untreated, non-
resectable
Intervention Cetuximab with 
chemotherapy
In combination with 
chemotherapy
Cetuximab plus 
FOLFIRI or FOLFOX
Cetuximab + FOLFIRI 
(CRYSTAL), cetuximab 
+ FOLFOX (OPUS)
Comparators Oxaloplatin-including 
regimens, irinotecan 
including regimens, 
5-FU/FA (including oral 
analogues, capecitabine 
and tegafur with uracil)
FOLFIRI or FOLFOX 
only
FOLFIRI (CRYSTAL), 
FOLFOX (OPUS)
EGFR, epidermal growth factor receptor; FA, folinic acid; FOLFIRI, irinotecan in combination with S-FU/FA; FOLFOX, S-FU 
and folinic acid (FA); FU, 5-fluorouracil; mCRC, metastatic colorectal cancer
Summary of submitted cost-
effectiveness evidence
No published economic evaluations of cetuximab 
for first-line chemotherapy in mCRC were 
identified in the submission, but additional 
searches by the ERG suggested that six cost-
effectiveness papers may have been of relevance. A 
de novo model examined the cost-effectiveness of 
cetuximab in patients with mCRC that was EGFR 
positive, k-ras wild type and with liver metastases. 
The model was a time dependent state transition 
(Markov) model with a cycle length of 1 week 
and a 23-year time horizon (1200 cycles). The 
main source of evidence came from the two RCTs 
(CRYSTAL and OPUS) and used progression-
free survival and mortality results. Other sources 
of cost and clinical model inputs were included 
such as Eastern Co-operative Oncology Group 
performance status, results of second and third-
line treatment, costs of k-ras (but not EGFR) tests 
and costs of hospitalisation. Sensitivity analyses 
(scenario, one-way and probabilistic) were 
performed and reported. A reworked economic 
model using inputs from the CELIM trial8 and the 
GERCOR trial9 was submitted between the first and 
second appraisal committee meetings.
Commentary on the robustness 
of submitted evidence
The strength of the submitted clinical effectiveness 
was because it was based on two RCTs rather than 
Cetuximab for the first-line treatment of metastatic colorectal cancer
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FIGURE 2 Survival curves for the CRYSTAL and OPUS trials
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a single RCT or non-RCT evidence, and then a 
further two trials were introduced. The original 
trials were sufficiently large and follow-up was 
sufficiently long {[commercial-in-confidence 
data removed] months for CRYSTAL and 12 
months for OPUS} to establish median survival 
times and obtain statistically significant results. 
However, only the k-ras wild-type subgroup of 
results was presented for clinical effectiveness. It 
was acknowledged in the submission that they were 
post hoc tests carried out for licensing purposes. 
In addition, a subgroup of liver metastases from 
the k-ras wild-type subgroup was also presented 
and it was these subgroup results that were used 
for the economic model. For the CRYSTAL and 
OPUS trials, respectively, the full intention-to-treat 
populations, k-ras wild-type subgroups and liver 
metastases subgroups of subgroups were 1198, 348 
and 67, and 336, 134 and 38.
The CELIM and GERCOR trials were introduced 
at the committee stage. For the CELIM trial, the 
inclusion criteria stated that patients were to have 
non-resectable liver metastases at baseline yet 
randomisation was stratified by whether the liver 
metastases were technically resectable or not, and 
evaluation of resectability occurred 4 months after 
randomisation. This seemed contradictory. The 
GERCOR trial compared using FOLFIRI first the 
FOLFOX to FOLFOX first the FOLFIRI in mCRC.
The Markov model was appropriate for the 
decision problem. Having two RCTs (CRYSTAL 
and OPUS) as the main source of clinical 
effectiveness evidence was a strength in that the 
two trials’ results were similar even though the 
comparator arms used different chemotherapy 
regimens (FOLFIRI and FOLFOX). Most of the 
other sources of cost and clinical model inputs 
were appropriate within the context of the model. 
Extensive and appropriate sensitivity analyses were 
conducted.
The model did not wholly address the problem 
as stated in the scope issued by NICE. Instead 
the model focused on the patients for whom the 
treatment had been licensed. This limited the 
applicability of the model to the NHS setting in 
which patients would be a mixture of k-ras wild type 
and mutations and also a mixture of patients with 
liver metastases and other metastases. Although the 
manufacturer cannot be held responsible for the 
differences between the licensed population and 
the population as set out in the NICE scope, strictly 
speaking the model did not answer the specified 
decision problem.
The model structure did not include provision 
for the identification of k-ras wild-type patients. 
In order to evaluate the cost-effectiveness of a 
treatment it is important to know the outcomes 
for all patients. In this case, the model assumed 
that all patients who were suitable for treatment 
were identified and treated (those who were k-ras 
wild type). It also assumed that no patients who 
were not suitable for treatment (those who were 
not k-ras wild type) were treated. No evidence is 
provided to support this key assumption. Given the 
importance of estimating the outcomes for those 
treated incorrectly (either not receiving treatment 
when they should receive it, or being incorrectly 
given treatment) in reaching a conclusion on the 
cost-effectiveness of the treatment, this omission 
from the model should be considered a serious flaw 
in the model design.
The reworked model had the same structure as 
the original, but it was difficult to determine how 
accurate the clinical effectiveness inputs from 
the CELIM and GERCOR trials were, given that 
neither were RCTs of cetuximab versus placebo.
Conclusions
The NICE scope did not specify the k-ras subgroup 
of patients so it is uncertain as to how the clinical 
effectiveness results presented matched the 
population specified in the decision problem. It is 
also uncertain as to how accurate k-ras testing is in 
clinical practice.
The effectiveness estimates for the economic 
model were based on 105 patients (67 CRYSTAL, 
38 OPUS). It is uncertain how accurate these 
effectiveness estimates are, given that they were 
derived from small post hoc subgroup analyses of 
trial results.
The lifetime time horizon selected for the 
model was the appropriate approach to take in 
a decision analysis such as the one submitted by 
the manufacturer. However, the average age of 
patients developing colorectal cancer and being 
treated in the NHS was in the region of 10 years 
greater than the average age assumed in the 
economic model. This limited the applicability of 
the results to the NHS. The manufacturer’s revised 
submission included a model that ran for 10 years 
to examine the impact that this would have on 
the results. Information from the CRYSTAL and 
OPUS trials was only available for a period of just 
over 1 year. Secondary information was used to 
Cetuximab for the first-line treatment of metastatic colorectal cancer
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estimate survival over a further 22-year period. 
This increased greatly the uncertainty in the 
results although this increased uncertainty was not 
discussed in sufficient detail.
The difference in median progression-free survival 
in the CRYSTAL trial, for the k-ras wild-type 
subgroup, was 1.2 months (9.9 months versus 8.7 
months) and for the OPUS trial was 0.5 months 
(7.7 months versus 7.2 months). Eight months’ 
treatment with cetuximab, given as an initial 
loading dose and then weekly until progression, 
would cost around £22,932 for an average man 
and £18,427 for an average woman. It is uncertain 
whether this constitutes good value for money.
Summary of NICE guidance 
issued as a result of the STA
At the time of writing, the Appraisal Consultation 
Document issued by NICE on 25 September 2008 
states that:
1. Cetuximab is not recommended for the first-
line treatment of metastatic colorectal cancer
2. People currently receiving cetuximab for the 
first-line treatment of metastatic colorectal 
cancer should have the option to continue 
treatment until they and their clinicians 
consider it appropriate to stop.
Final NICE guidance was issued in August 2009 
recommending cetuximab treatment in this 
population subject to a number of important 
constraints. 
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of infliximab for 
the treatment of acute exacerbations of ulcerative 
colitis, in accordance with the licensed indication, 
based upon the manufacturer’s submission to 
the National Institute for Health and Clinical 
Excellence (NICE) as part of the single technology 
appraisal process. The submitted clinical evidence 
included four randomised controlled trials (RCTs), 
two comparing infliximab with placebo in patients 
not responsive to initial treatment with intravenous 
corticosteroids and one comparing ciclosporin 
with placebo. A fourth RCT compared ciclosporin 
with intravenous corticosteroids as the initial 
treatment after hospitalisation. The manufacturer’s 
submission concluded that infliximab provides 
clinical benefit to patients with acute severe, 
steroid-refractory ulcerative colitis and is well 
tolerated; it also provides additional clinical 
benefits over ciclosporin, particularly avoidance 
of colectomy. A decision tree model was built 
to compare infliximab with strategies involving 
ciclosporin, standard care and surgery. After 
correcting a small number of errors in the model, 
the revised base-case incremental cost-effectiveness 
ratio (ICER) for infliximab compared with standard 
care was £20,000. However, sensitivity analyses 
revealed considerable uncertainty emanating 
from the weight of the patient, the timeframe 
considered and, most importantly, the colectomy 
rates used. When a more appropriate mix of trials 
were included in the estimation of colectomy 
rates, the ICER for infliximab rose to £48,000. 
DOI: 10.3310/hta14suppl1/02
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The guidance issued by NICE on 31 October 
2008 states that infliximab is recommended as an 
option for the treatment of acute exacerbations of 
severely active ulcerative colitis only in patients in 
whom ciclosporin is contraindicated or clinically 
inappropriate, based on a careful assessment of the 
risks and benefits of treatment in the individual 
patient; for people who do not meet this criterion, 
infliximab should only be used for the treatment 
of acute exacerbations of severely active ulcerative 
colitis in clinical trials.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, where most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the 
STA entitled ‘Infliximab for the treatment of acute 
exacerbations of ulcerative colitis’.
Description of the underlying 
health problem
Ulcerative colitis (UC) is a chronic condition in 
which there is inflammation of the mucosa of 
the large intestine. The cause of UC is unknown. 
Hereditary, infectious and immunological factors 
have been proposed as possible causes.
The incidence of UC is approximately 10–20 per 
100,000 per year with a reported prevalence of 
100–200 per 100,000 in the UK. This prevalence 
is likely to be an underestimate as this implies an 
average disease duration of 10 years for a condition 
that is known to last for life. Based on these 
prevalence figures there are between 52,794 and 
105,587 people in England and Wales with UC. 
The age of onset peaks between 20 and 40 years 
of age, but the disease may present at all ages. The 
prevalence of UC in children is about six to seven 
per 100,000 in the UK.
The symptoms of UC vary according to the extent 
and severity of the inflammation. The classic 
symptom of UC is bloody diarrhoea. Associated 
symptoms of colicky abdominal pain, urgency 
or tenesmus may be present. Mildly active UC is 
defined as less than four bowel movements daily. 
Moderately active UC is defined as more than four 
daily bowel movements, but where the patient is 
not systemically ill. Severe UC is defined as an 
attack in which the patient has more than six bowel 
movements daily and is systemically ill as shown by 
tachycardia, fever or anaemia. Fulminant disease 
correlates with more than 10 bowel movements 
daily, continuous bleeding, toxicity, abdominal 
tenderness and distension, blood transfusion 
requirement and colonic dilation (expansion). 
Patients in this category may have inflammation 
extending just beyond the mucosal layer, causing 
impaired colonic motility and leading to toxic 
megacolon (toxic dilation of the colon).
Approximately 90% of all incident cases of UC are 
mild or moderate in severity.
In UC the severity of the symptoms fluctuate 
unpredictably over time with intervals of remission 
or reduced symptoms. Approximately 50% of 
patients with UC have a relapse in any year. A 
significant minority have frequently relapsing or 
chronic continuous disease. Twenty-five per cent 
of patients with severe UC are admitted to an 
inpatient setting with flares of UC that are not 
responding to steroids. An estimated 20–30% of 
patients with pancolitis (disease affecting the entire 
colon) will require colectomy.
Complications of UC may include haemorrhage, 
perforation, stricture formation, abscess formation, 
anorectal disease (e.g. fissures), arthritis, eye, 
cutaneous and liver abnormalities. Patients with 
long-standing dysplasia and extensive colitis 
have an increased risk of bowel cancer. UC has a 
slight excess of mortality in the first 2 years after 
diagnosis, but little subsequent difference from 
the general population. A severe attack of UC is a 
potentially life threatening illness.
The British Society of Gastroenterology 
published guidelines for the treatment of UC 
in 2004. The main recommendations for the 
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medical management of severe UC indicate that 
patients whose condition has not responded 
to maximal oral treatment with a combination 
of mesalazine and/or corticosteroids should be 
admitted for intensive intravenous therapy. When 
hospitalised, patients are usually given intravenous 
corticosteroids and, if there is no improvement 
during the first 3 days, surgical intervention or 
intravenous ciclosporin is considered. Following 
induction of remission, patients with UC should 
normally receive maintenance therapy with 
aminosalicylates and often also azathioprine or 
mercaptopurine and/or short-term ciclosporin 
to reduce the risk of relapse. Patients frequently 
receive combination therapies. Severe UC should 
be managed jointly by a gastroenterologist in 
conjunction with a colorectal surgeon within a 
multidisciplinary team with specialist nursing 
support.
Infliximab (Remicade, Schering Plough) is a 
chimeric monoclonal antibody that binds with 
high affinity to tumour necrosis factor-a, thereby 
neutralising its activity. It is administered by 
intravenous infusion and is licensed for moderately 
to severely active UC in patients who have had 
an inadequate response to conventional therapy 
including corticosteroids and 6-mercaptopurine 
or azathioprine, or who are intolerant to or have 
medical contraindications for such therapies.
Scope of the evidence 
review group report
The purpose of the ERG report was to comment 
on the validity of the manufacturer’s submission 
on the technology of interest. The scope for this 
submission and hence the scope for the ERG report 
is shown in Table 1.
Methods
The ERG report comprised a critical review of 
the evidence for the clinical evidence and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process.
Specific steps undertaken by the ERG included:
• discussion of the nature of the problem with a 
clinical expert
• reanalysis of the nature of the underlying 
clinical question
• rerunning searches indicated to have been 
performed to inform the manufacturer’s 
submission
• extending searches, particularly for ongoing 
trials
• formal critical appraisal of systematic review 
underpinning the manufacturer’s submission, 
and two related Cochrane Reviews
• reappraisal and checking of data abstraction on 
the four key included studies
• rerunning of mixed treatment comparison 
model
• checking the consistency of the direct 
effectiveness evidence with the estimates 
emerging from the mixed treatment 
comparison model and the parameters used in 
the economic model
• rerunning of the economic model supplied by 
the company
• correcting minor programming errors
• additional sensitivity analyses within the limits 
of the facilities of the submitted model.
The work was carried out between 17 April 2008 
and 18 June 2008.
Members of the ERG team attended and advised 
the meeting of the NICE appraisal committee 
where this guidance was discussed on 17 July 2008.
Results
Summary of submitted 
clinical evidence
The manufacturer’s submission reviewed systematic 
reviews and randomised controlled trials (RCTs) 
of infliximab and ciclosporin, the main alternative 
treatment option. The review also examined non-
RCT evidence, particularly case-series of infliximab 
in the patient group of interest, but this did not 
contribute to the conclusions and is not considered 
further in this summary.
The main evidence identified is well known, four 
RCTs, two2,3 comparing infliximab with placebo 
in patients not responsive to initial treatment with 
intravenous corticosteroids and one4 comparing 
ciclosporin with placebo. A fourth RCT5 compared 
ciclosporin with intravenous corticosteroids as the 
initial treatment after hospitalisation. The evidence 
on effectiveness was combined through a mixed 
treatment comparison model.
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The review and the model contribute to the two 
main conclusions offered in the manufacturer’s 
submission:
• Infliximab provides clinical benefit to patients 
with acute severe, steroid-refractory UC and is 
well tolerated.
• Infliximab provides additional clinical benefits 
over ciclosporin, particularly avoidance of 
colectomy.
Summary of submitted cost-
effectiveness evidence
No published economic evaluations of infliximab 
in acute UC were identified and so the cost-
effectiveness work focused entirely on the de 
novo model and economic evaluation undertaken 
by the manufacturer. A decision tree model 
was built to compare infliximab with strategies 
involving ciclosporin, standard care and surgery. 
The main evidence used to estimate some of the 
key probabilities in the model derived from the 
main trials, but data on resource use and costs 
were available only from an expert panel. Utility 
data were taken from an observational cohort 
(the HODaR study; Health Outcomes Data 
Repository). The results revealed dominance in 
the comparison of standard care and ciclosporin. 
On the basis of the results, it is clear that the 
move from standard care to ciclosporin is highly 
cost-effective given that it is associated with lower 
costs and higher quality-adjusted life-years. Thus, 
the policy question then to be addressed is the 
subsequent move from ciclosporin to infliximab, 
and so the only appropriate comparator for 
infliximab is ciclosporin. After correcting a small 
number of errors in the model, the revised base-
case incremental cost-effectiveness ratio (ICER) 
for infliximab compared with standard care was 
TABLE 1 Submission scope
Component of 
submission scope Detail of submission scope
Appraisal objective To appraise the clinical effectiveness and cost-effectiveness of infliximab for the treatment of acute 
exacerbations of severely active UC that require hospitalisation
Intervention(s) Infliximab
Population(s) Adults with acute exacerbations of severely active ulcerative colitis who have had an inadequate 
response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, 
or who are intolerant to or have medical contraindications for such therapies, and whose clinical 
management requires hospitalisation
Standard comparators The standard comparators to be considered include:
 – standard clinical management which may include surgical intervention
 – ciclosporin
Outcomes The outcome measures to be considered included:
 – health-related quality of life
 – survival
 – rates of and duration of response, relapse and remission
 – rates of surgical intervention
 – measures of disease activity
 – adverse effects of treatment
Economic analysis The reference case stipulated that the cost-effectiveness of treatments should be expressed in 
terms of incremental cost per quality-adjusted life-year
Time horizon should be long enough to allow reasonable estimation of expected costs (including 
adverse events if applicable) and benefits for the intervention, but should also account for the 
disease specific feature, particularly fluctuation and unpredictability of symptoms
Costs were considered from an NHS and Personal Social Services perspective
Other considerations Where evidence permits, the appraisal of infliximab for the acute exacerbation of severely active 
UC should identify patient subgroups for whom the technology is most appropriate
Where evidence permits, the appraisal of infliximab for the acute exacerbation of severely active 
UC should consider different posology or methods of administration, treatment continuation 
strategies and lengths of treatment required when patients have responded to infliximab
Guidance will only be issued in accordance with the Summary of Product Characteristics
Related NICE 
recommendations
Related ongoing technology appraisals: Infliximab for the sub-acute manifestation of ulcerative 
colitis.
Related guidelines: none
Health Technology Assessment 2010; Vol. 14: Suppl. 1
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
13
£20,000. However, sensitivity analyses revealed 
considerable uncertainty emanating from the 
weight of the patient, the timeframe considered 
and, most importantly, the colectomy rates used. 
When a more appropriate mix of trials was 
included in the estimation of colectomy rates, the 
ICER for infliximab rose to £48,000.
Commentary on the robustness 
of submitted evidence
Strengths
The review of effectiveness was generally systematic 
in approach, building on previous work in the area.
The submission reported a de novo model-based 
economic evaluation that has considered the cost-
effectiveness of infliximab in UC. The use of a 
decision tree model was appropriate, as the focus 
is on the acute phase of the disease. The main 
probability inputs were derived from trial data.
Probabilistic sensitivity analysis and one-way 
sensitivity analyses were performed.
Weaknesses
Although generally systematic, the review of clinical 
effectiveness had some errors, most notably failing 
to distinguish that the effect measured by one of 
the included RCTs5 is qualitatively different from 
the other trials and should not be combined with 
them. There was concern that the considerable 
uncertainty surrounding the estimates of 
effectiveness arising from the very small number of 
RCTs, which are themselves small, was understated. 
Although the mixed treatment comparison model 
is interesting, it is debatable whether the very 
limited amount of data available warranted such a 
sophisticated approach.
The model did not consider side-effect issues or 
mortality events. The resource use estimates used 
in the model were from an expert panel. The key 
model inputs on colectomy rates were derived from 
a small number of small trials, some of which may 
not be directly relevant to the policy question being 
addressed.
Conclusions
Several areas of uncertainty were identified:
• There was considerable uncertainty about 
the evidence on effectiveness of infliximab 
and ciclosporin. Primarily this emanates from 
the very limited amount of RCT data, the 
impact of which was somewhat understated 
in the manufacturer submission. This was 
compounded by a debatable decision about 
‘combining’ the data for an RCT with a 
control arm of intravenous corticosteroids 
with RCTs with placebo control arms and the 
use of a mixed treatment comparison model 
to generate estimates of the effect infliximab 
versus ciclosporin for which there is no direct 
evidence. This however also led to estimates 
of effect of infliximab and ciclosporin that 
differed in important respects from the original 
trials (Tables 2 and 3).
• The results consistently indicated that the move 
from standard care to ciclosporin is highly 
cost-effective. Thus, the appropriate policy 
question is not uncertain. The question to be 
addressed was: should we make a subsequent 
move from ciclosporin to infliximab? And so 
the only appropriate comparator for infliximab 
is ciclosporin.
• There was considerable uncertainty concerning 
what colectomy rates should be used.
• The weight of the patient was important – if 
patients tended to be 60 kg or less then the 
cost-effectiveness of infliximab was more 
attractive.
• The timeframe of the model was also 
important – extrapolating beyond 12 months 
was the approach that is consistent with the 
NICE methods guide. Such extrapolation 
indicates worsening cost-effectiveness for 
infliximab in general.
The key issues for consideration by the appraisal 
committee were thus suggested to be:
• Was the effectiveness of both infliximab 
and ciclosporin accurately portrayed by the 
manufacturer submission, particularly through 
the ‘inclusion’ of the RCT of ciclosporin 
by D’Haens et al.,5 and through the use of 
the mixed treatment comparison model to 
summarise and estimate parameters for the 
economic model?
• Did the manufacturer’s submitted model fully 
capture and convey the uncertainty arising 
from the problems with the effectiveness data?
• From the information available was it likely 
that improved estimates of effectiveness, 
and therefore cost-effectiveness, would arise 
from the ongoing trials of infliximab versus 
ciclosporin identified?
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TABLE 2 Colectomy 0- to 3-month results [event rates and odds ratios (ORs)] from different parts of the report 
Intervention Jarnerot2 Sands3 Lichtiger4 D’Haens5 MTC model
Crude rates (%) [95% CI by Wilson’s method]
Infliximab 7/24 (0.29)  
[0.15 to 0.49]
0/3 (0.0)  
[0.0 to 0.56]
(0.23)  
[0.05 to 0.56]
Ciclosporin 3/11 (0.27)  
[0.10 to 0.57]
3/14 (0.21)  
[0.08 to 0.48]
(0.58)  
[0.22 to 0.88]
Placebo 14/21 (0.67)  
[0.45 to 0.83]
3/3 (1.0)  
[0.44 to 1.0]
4/9 (0.44)  
[0.19 to 0.73]
3/15 (0.20)  
[0.07 to 0.45]
(0.67)  
[0.46 to 0.85]
Odds ratio [95% CI]
Infliximab vs 
placebo
0.21  
[0.06 to 0.73]a
0a 0.13  
[0.03 to 0.44]
Ciclosporin vs 
placebo
0.47  
[0.07 to 3.04]b
1.09 [0.18 to 6.58] 0.70  
[0.18 to 2.69]
Infliximab vs 
ciclosporin
No direct 
comparisons
CI, confidence interval; MTC, mixed treatment comparison.
a Combined result from meta-analysis of Jarnerot and Sands, supplied by manufacturer in response to request for 
supplementary information, summary OR (fixed effects) 0.16 (0.05 to 0.53), Summary OR (random effects) 0.16 (0.04 to 
0.66).
b Equivalent to relative risk of 0.61 (0.18 to 2.1).
TABLE 3 Colectomy 3- to 12-month results [event rates and odds ratios (ORs)] from different parts of the report
Intervention Jarnerot2 Sands3 Lichtiger4 D’Haens5 MTC model
Crude rates (%) [95% CI by Wilson’s method]
Infliximab 3/17 (0.18)  
[0.06 to 0.41]
(0.27)  
[0 to 0.92]
Ciclosporin 3/11 (0.27)  
[0.10 to 0.57]
(0.18)  
[0.0 to 0.70]
Placebo 1/7 (0.14)  
[0.03 to 0.51]
3/12 (0.25)  
[0.09 to 0.53]
(0.14)  
[0.0 to 0.47]
Odds ratio [95% CI]
Infliximab vs 
placebo
1.3  
[0.11 to 15.0]
1.8  
[0.13 to 57]
Ciclosporin vs 
placebo
1.1  
[0.18 to 7.2]
1.1  
[0.15 to 8.5]
Infliximab vs 
cºiclosporin
No direct 
comparisons
CI, confidence interval; MTC, mixed treatment comparison.
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Summary of NICE guidance 
issued as a result of the STA
At the time of writing, the Final Appraisal 
Determination document issued by NICE on 31 
October 2008 states that:
This guidance relates only to the use of infliximab 
within its marketing authorisation, for the 
treatment of acute exacerbations of severely active 
ulcerative colitis. It relates to an induction course of 
three doses of infliximab.
1.1 Infliximab is recommended as an option 
for the treatment of acute exacerbations of 
severely active ulcerative colitis only in patients 
in whom ciclosporin is contraindicated or 
clinically inappropriate, based on a careful 
assessment of the risks and benefits of 
treatment in the individual patient.
1.2 In people who do not meet the criterion in 
1.1, infliximab should only be used for the 
treatment of acute exacerbations of severely 
active ulcerative colitis in clinical trials.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of sorafenib 
according to its licensed indication for advanced 
hepatocellular carcinoma (HCC). The ERG report 
was based on the manufacturer’s submission to 
the National Institute for Health and Clinical 
Excellence (NICE) as part of the single technology 
appraisal process. The licensed indication for 
sorafenib specifies advanced HCC patients for 
whom locoregional intervention and surgery are 
unsuitable or had been unsuccessful. The clinical 
evidence came from a multicentre randomised 
controlled trial (Sorafenib HCC Assessment 
Randomized Protocol; SHARP) of sorafenib 
plus best supportive care versus placebo plus 
best supportive care, with 602 participants of 
a predominantly European ethnicity broadly 
comparable to the UK population. The submitted 
evidence indicated that for advanced HCC patients 
with Child–Pugh grade A liver function and 
relatively good Eastern Cooperative Oncology 
Group performance status, sorafenib on average 
improves overall survival by 83 days relative to 
placebo, and also increases time-to-radiological 
disease progression. Sorafenib therapy had little 
or no effect on time-to-symptom progression or on 
quality of life as measured using a disease-specific 
questionnaire. Sorafenib treatment was associated 
with increased incidence of hypertension and of 
gastrointestinal and dermatological problems. 
However, the therapy was reasonably well tolerated 
DOI: 10.3310/hta14suppl1/03
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and, in SHARP, withdrawals from treatment due 
to adverse events were similar in the sorafenib and 
placebo arms, although more temporary reductions 
in dose were required in the sorafenib than in the 
placebo group. In the base case, the manufacturer’s 
submitted economic analysis generated a 
deterministic incremental cost-effectiveness ratio 
(ICER) of £64,754 per quality-adjusted life-year 
(QALY). The ERG extracted individual patient data 
for overall survival and disease progression, reran 
the economic model to check the submitted cost-
effectiveness results, and performed new analyses 
which the ERG considered relevant to the decision 
problem; these analyses delivered ICERs between 
£76,000/QALY and £86,000/QALY. The guidance 
issued by NICE (7 May 2009) stated that sorafenib, 
within its licensed indication, is not recommended 
for the treatment of advanced (Barcelona-Clínic 
Liver Cancer stage C) HCC patients for whom 
surgical or locoregional therapies have failed or 
are not suitable, and people currently receiving 
sorafenib for the treatment of HCC should have 
the option to continue treatment until they and 
their clinician consider it appropriate to stop. 
Subsequently the manufacturer submitted a patient 
access scheme to the Department of Health. The 
base-case ICER submitted by the manufacturer for 
this scheme was £51,899/QALY. When the ERG 
reran the model with inputs considered relevant 
to the decision problem the ICER estimates 
ranged between £53,000 to £58,000/QALY and 
substantially higher values depending on the 
nature of the sensitivity analyses. NICE considered 
the impact of the patient access scheme and 
determined that it was not sufficient to alter the 
guidance.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, where most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG); an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report2 for the 
STA submission3 that considered the clinical 
effectiveness and cost-effectiveness of sorafenib for 
advanced hepatocellular carcinoma in patients for 
whom locoregional intervention and surgery were 
unsuitable or had been unsuccessful.
Description of the underlying 
health problem
Hepatocellular carcinoma (HCC) is a rare disease 
in the UK, with approximately 2340 patients 
diagnosed annually in England and Wales. HCC 
is associated with a number of underlying liver 
conditions and primary risk factors and these 
include hepatitis virus infection, alcoholism and 
biochemical insult from agents such as aflatoxin. 
Almost invariably HCC patients have compromised 
liver function which is currently graded according 
to the Child–Pugh system into grades A–C of 
increasing severity. Owing to the often underlying 
liver disease, it is difficult to disentangle patient 
symptoms that relate to HCC from those of the 
underlying condition. As in other European 
countries, incidence of HCC in the future is 
likely to increase because of the growing levels 
of hepatitis virus C infection in the population 
in previous years. Therapeutic options in HCC 
include liver transplant, surgical resection, loco-
regional therapies such as ablation and chemo-
embolisation, and systemic therapy with drugs such 
as doxorubicin (infused) or oral sorafenib.
The prognosis for HCC patients is poor and life 
expectancy after diagnosis is more likely to be 
months than years. Several HCC staging schemes 
have been developed; of these the Barcelona-Clínic 
Liver Cancer (BCLC) system4 is widely used and 
classifies patients as stage A–D where stage A is 
‘early’ disease, stage B is ‘intermediate disease’, 
stage C is ‘advanced’ disease and stage D patients 
are classified as having ‘end stage’ disease.5,6
Scope of the evidence 
review group report
The research question posed for the STA was: 
what is the effectiveness and cost-effectiveness of 
sorafenib (Nexavar®) in the treatment of advanced 
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HCC when surgical or locoregional therapies have 
failed or are unsuitable?
Sorafenib is a newly developed systemic therapy 
previously licensed for use in renal cancer and 
more recently licensed for HCC.
The clinical effectiveness data came from a 
multicentre randomised controlled trial (RCT) 
(Sorafenib HCC Assessment Randomized Protocol; 
SHARP) of sorafenib plus best supportive care 
versus placebo plus best supportive care, with 602 
participants of a predominantly European ethnicity 
and broadly comparable to the UK population.7 
The submission was based on the premise that ‘the 
phase III SHARP study is the largest and most 
relevant data source for the decision problem 
being addressed’. Important outcomes measured in 
SHARP were overall survival, time-to-symptomatic 
progression, time-to-disease (i.e. tumour) 
progression, and quality of life. Other outcomes 
measured included tumour and disease response 
rates. Two other small effectiveness studies were 
used for supportive evidence only; these were 
one RCT – the Asia-Pacific study8 – of sorafenib 
versus placebo with 226 patients, and one open-
label uncontrolled study9,10 with 136 patients. The 
potential benefits of sorafenib treatment compared 
with supportive care are extended life span and 
increased quality-adjusted life-years (QALYs) 
gained, with tolerable burden of drug side effects.
The submission’s estimation of resource use and 
costs for the cost-effectiveness analyses relied 
heavily on expert opinion.
Methods
The ERG reran the submission’s search strategy, 
constructed and ran an independent search 
strategy broader than that in the submission, and 
applied less ambiguous inclusion and exclusion 
criteria than those in the submission in order to 
ascertain if relevant studies were missing from the 
submission.
The ERG appraised the submission’s critical 
appraisal of the quality of the SHARP study.
The ERG checked the SHARP data in the 
submission against those in the published account 
of SHARP and also those in the full trial report that 
was requested from the manufacturer.
The ERG extracted individual patient data for 
overall survival from the SHARP trial report 
and performed independent survival analysis in 
order to test assumptions made in the submission 
regarding the use of the hazard ratio statistic.
The ERG extracted individual patient data for 
time-to-treatment progression from the SHARP 
trial report, checked the accuracy of this data 
extraction, and then performed survival analysis 
using extracted data to generate input parameters 
necessary to undertake sensitivity analysis of the 
submission’s economic model which the ERG 
considered to be relevant to the decision problem.
The ERG checked the supportive evidence data 
presented in the submission against those in the 
publications of the two supportive studies (Asia-
Pacific RCT8 and open-label uncontrolled study9,10).
The ERG extracted data from a publication 
presenting results from the open-label uncontrolled 
supportive study which had not been included in 
the submission, but which the ERG considered 
to be relevant to the decision problem. The ERG 
summarised the implications of these data.
The ERG checked the published algorithm used in 
the submission to calculate health utilities for input 
to the economic model.
The ERG checked the internal validity of the 
submitted economic model, reran the economic 
model to check the submitted cost-effectiveness 
results and performed new sensitivity analyses 
which the ERG considered relevant to the decision 
problem.
Results
Summary of submitted 
clinical evidence
The submitted evidence indicated that relative 
to placebo, sorafenib extended overall median 
survival by 83 days (11.9 weeks) and also extended 
time-to-disease radiological (tumour) progression; 
two different assessments of time-to-tumour 
progression were submitted. Sorafenib therapy had 
little or no effect on time-to-symptom progression 
or on quality of life as measured using a disease-
specific questionnaire (Functional Assessment 
of Cancer Therapy-Hepatobiliary; FACT-Hep). 
Sorafenib treatment was associated with increased 
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incidence of hypertension11 and of gastrointestinal 
and dermatological problems.12 However, the 
therapy was reasonably well tolerated and, in 
SHARP, withdrawals from treatment due to adverse 
events were similar in the sorafenib and placebo 
arms, although more temporary reductions in dose 
were required in the sorafenib than in the placebo 
group.
Summary of submitted cost-
effectiveness evidence
In the base case, the economic model generated 
a deterministic incremental cost-effectiveness 
ratio (ICER) of £45,502 per life-year and £64,754 
per QALY. Probabilistic analysis generated a 50% 
probability of cost-effectiveness at a willingness 
to pay of £45,832 per life-year and £65,244 per 
QALY.
In a best-case scenario, the model generated an 
ICER of £39,627 per life-year and £55,729 per 
QALY. In a best-case scenario for subgroups, ICERs 
of £16,794 per life-year and £24,620 per QALY 
were generated.
Commentary on the robustness 
of submitted evidence
The submitted evidence was based almost 
exclusively on clinical effectiveness results for 
patients with relatively mild impairment of liver 
function (Child–Pugh grade A) and with relatively 
good performance status [Eastern Cooperative 
Oncology Group (ECOG) performance status 
criteria]. The ERG did not identify any errors 
in the submission’s data extraction, although 
there was an omission of some limited evidence 
relating to the effectiveness of sorafenib for Child–
Pugh grade B patients. The results from SHARP 
demonstrated significant improvements in overall 
survival and in time-to-disease progression; these 
observations were supported by the Asia-Pacific 
randomised trial in a population of different 
ethnicity and considerably different HCC aetiology.
The best-case economic analysis submitted was 
inappropriate to the decision problem because the 
patient group (BCLC stage B ‘intermediate’ HCC) 
could not be classified as having advanced disease. 
In the context of uncertainty about the time-to-
disease progression, the ERG undertook sensitivity 
analysis of the base-case scenario, which generated 
ICERs of £76,000 per QALY and £85,805 per 
QALY.
Conclusions
For HCC patients with Child–Pugh grade A liver 
function and relatively good ECOG performance 
status, sorafenib on average improves overall 
survival by 83 days and also increases time-to-
disease progression compared with best supportive 
care. Available evidence does not indicate that it 
delays symptom progression or improves quality of 
life.
It is uncertain if sorafenib is equally effective for 
patients with poorer liver function than Child–
Pugh grade A or for those of poor performance 
status, but the small amount of evidence available 
implies that it may not be.
Sensitivity analysis indicates that the ICER for 
patients like those in SHARP may be greater than 
the submitted values of £45,502 per life year and 
£64,754 per QALY.
Key issues for the decision problem and areas of 
uncertainty are:
• To what extent does the clinical effectiveness 
observed in SHARP apply to the broader 
population of patients defined by the decision 
problem (i.e. a broader range of liver function 
insufficiency)?
• By how much is time-to-disease progression 
improved?
• What is the quality of life for patients 
administered sorafenib?
Summary of NICE guidance 
issued as a result of the STA
The guidance appraisal consultation document 
issued by NICE (7 May 2009) stated that 
the Appraisal Committee’s preliminary 
recommendations were:
1.1 Sorafenib, within its licensed indication, is not 
recommended for the treatment of advanced 
(Barcelona clinic liver cancer [BCLC] stage C) 
hepatocellular carcinoma (HCC) in patients for 
whom surgical or locoregional therapies have 
failed or are not suitable.
1.2 People currently receiving sorafenib for the 
treatment of HCC should have the option 
to continue treatment until they and their 
clinician consider it appropriate to stop. 
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Subsequent to the preliminary NICE guidance, the 
Department of Health (DoH) accepted a patient 
access scheme (PAS) proposed by the manufacturer. 
The detail of this scheme is confidential. The 
DoH were content for NICE to consider the 
consequences of the PAS in their deliberations. The 
manufacturer supplied a revised economic model 
and associated analyses to indicate the effect of 
the PAS on the cost-effectiveness of sorafenib. The 
ERG checked the internal validity of the submitted 
economic model, reran the economic model to 
check the submitted cost-effectiveness results and 
performed new analyses which the ERG considered 
relevant to the decision problem and the 
implementation of the PAS. The manufacturer’s 
base-case analysis for the PAS gave an ICER of 
£51,899 per QALY. The ERG’s sensitivity analysis 
around the base case generated ICERs of £52,641 
to £58,147 per QALY and substantially higher 
values depending on the nature of the sensitivity 
analyses.
After considering analyses on the PAS the 
NICE Appraisal Committee’s preliminary 
recommendations were unchanged (as of 9 
September 2009).
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of tenofovir 
disoproxil fumarate for the treatment of chronic 
hepatitis B, in accordance with the licensed 
indication, based upon the evidence submission 
from Gilead to the National Institute for Health 
and Clinical Excellence (NICE) as part of the 
single technology appraisal process. The submitted 
clinical evidence included two international 
randomised controlled trials (RCTs) comparing 
tenofovir with adefovir, and a mixed treatment 
comparison (MTC) using Bayesian methodology 
to compare tenofovir with other nucleos(t)
ide analogues using direct and indirect RCT 
evidence. There were no statistically significant 
differences between tenofovir and adefovir in 
overall adverse events although, in hepatitis B ‘e’ 
antigen (HBeAg)-positive patients, there was a 
higher incidence of mild nausea in the tenofovir 
treatment group. The primary outcome, ‘complete 
response’, was a composite end point defined as 
histology response and hepatitis B virus DNA 
below 400 copies/ml. For both HBeAg-positive 
and HBeAg-negative patients, a significantly 
greater proportion had a complete response 
after 48 weeks with tenofovir than with adefovir. 
There was no statistically significant difference in 
histological response in either group of patients 
compared with adefovir. The MTC could only 
generate results for HBeAg positive nucleos(t)ide 
naive patients as there was insufficient evidence 
for other subgroups. The probability of achieving 
undetectable HBV DNA with tenofovir was found 
to be significantly higher than that for all other 
treatments considered in the analysis at the 
DOI: 10.3310/hta14suppl1/04
Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection
24
0.05 level. The analysis demonstrated that there 
is a 98% probability that tenofovir is the most 
potent nucleos(t)ide in terms of this outcome. 
The manufacturer’s submission concluded that 
tenofovir is a cost-effective option as first-line 
treatment. For HBeAg-positive patients, tenofovir 
followed by lamivudine has an incremental 
cost-effective ratio (ICER) of £9940 per quality-
adjusted life-year (QALY) gained, compared 
with lamivudine followed by tenofovir. A more 
appropriate treatment strategy of tenofovir 
followed by tenofovir plus lamivudine has an 
ICER of £13,619 per QALY gained, compared 
with lamivudine followed by tenofovir. For 
HBeAg-negative patients, tenofovir followed by 
lamivudine has an ICER of £9811 per QALY 
gained, compared with best supportive care. A 
more clinically appropriate treatment strategy of 
tenofovir followed by tenofovir plus lamivudine has 
an ICER of £13,854 per QALY gained, compared 
with tenofovir followed by lamivudine. The ERG 
uncovered a number of errors in the submission 
and these ICERs approximately doubled when 
the analysis was corrected and reran. The 
guidance issued by NICE on 22 July 2009 states 
that tenofovir disoproxil, within its marketing 
authorisation is recommended as an option for the 
treatment of people with chronic HBe-Ag-positive 
or HBe-Ag-negative hepatitis B in whom antiviral 
treatment is indicated.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, where most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG); an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
entitled ‘Tenofovir disoproxil fumarate for the 
treatment of chronic hepatitis B’.2
Description of the underlying 
health problem
Hepatitis B is an infectious disease of the liver 
caused by the hepatitis B virus (HBV). It is 
transmitted through blood-to-blood contact 
(e.g. through sharing of blood-contaminated 
needles by drug users) and sexual contact. It is 
also transmitted vertically from mother to infant, 
during or soon after birth. Infected individuals 
develop an acute infection, which may or may 
not result in symptoms. The majority of those 
infected during adulthood make a full recovery 
and acquire immunity from future infection. 
About only 2–10% of infected adults will develop 
chronic hepatitis B (CHB), defined as viraemia and 
hepatic inflammation that persists for more than 6 
months after acute infection with HBV. In contrast, 
almost 100% of infected neonates and about 50% 
of infected young children will develop CHB if 
infected with HBV.
According to whether hepatitis B ‘e’ antigen 
(HBeAg) is secreted, active infection can be 
described as HBeAg-positive or HBeAg-negative. 
HBeAg is an indicator of viral replication, although 
some variant forms of the virus do not express 
HBeAg. The response to treatment and rates 
of progression differ between the two forms. 
People can be infected with the so-called HBeAg-
negative form of the virus from the beginning, 
or the viral mutation can emerge later in the 
course of infection in people initially infected with 
the HBeAg-positive form of the virus. Chronic 
infection with mutant strains of HBV that do not 
produce the ‘e’ antigen (that is, HBeAg-negative) 
is associated with a fluctuating course and a poor 
prognosis.
The Department of Health estimated that about 
180,000 people in the UK had CHB in 2002, 
but recent data from the Hepatitis B Foundation 
estimated that approximately 326,000 people are 
currently infected in the UK. There are about 7700 
new cases of CHB each year. Of these, around 300 
people were infected within the UK; the remainder 
(mainly immigrants to the UK) were infected 
abroad.
The progression to cirrhosis occurs at an annual 
rate of 2–5.5%, with a cumulative 5-year rate of 
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progression of 8–20% in HBeAg-positive CHB and 
an annual rate of 8–10% in HBeAg-negative CHB.
Scope of the evidence 
review group report
The ERG critically evaluated the evidence 
submission from Gilead on the use of tenofovir for 
the treatment of CHB. Tenofovir has a marketing 
authorisation in the UK for the treatment of 
chronic HBV infection in adults with compensated 
liver disease and evidence of active viral 
replication, persistently elevated serum alanine 
aminotransferase (ALT) levels and histological 
evidence of active inflammation and/or fibrosis.
The population considered in the scope was 
adults with active CHB according to the licensed 
indication. Patient subgroups included those with 
HBeAg-positive and HBeAg-negative CHB; and 
those who are treatment (nucleoside analogue) 
naive or refractory to lamivudine. Patients with co-
infections (e.g. HIV) were excluded in accordance 
with the scope. The intervention was tenofovir 
alone or in combination with other therapies.
Comparators included lamivudine, adefovir 
dipivoxil, entecavir and telbivudine.
Outcomes included HBeAg/hepatitis B surface 
antigen (HbsAg) seroconversion rate, virological 
response (HBV DNA); histological improvement 
(liver inflammation and fibrosis); biochemical 
response (e.g. ALT levels); development of 
viral resistance; and adverse events. Outcomes 
included in the scope and decision problem, but 
not reported in the submission include time-to-
treatment failure, survival and health-related 
quality of life.
Methods
The ERG report comprised a critical review of 
the evidence for the clinical evidence and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process.
The ERG checked the literature searches and 
applied the NICE critical appraisal checklist to 
the included studies and checked the quality of 
the manufacturer’s submission with the Centre 
for Reviews and Dissemination (CRD) quality 
assessment criteria for a systematic review. Searches 
were rerun in PubMed from August 2007 to 3 
December 2008 and results screened for potentially 
relevant randomised controlled trials (RCTs) 
of tenofovir. In addition, the ERG checked and 
provided commentary on the manufacturer’s model 
using standard checklists. The ERG conducted an 
amended base-case analysis, a one-way sensitivity 
analysis, a scenario analysis and a probabilistic 
sensitivity analysis to correct for errors in the 
manufacturer’s economic model.
Results
Summary of submitted 
clinical evidence
The evidence in the manufacturer’s submission 
comprised (i) a systematic review which included 
two international RCTs comparing tenofovir 
with adefovir,3,4 and (ii) and a mixed treatment 
comparison (MTC) using Bayesian methodology 
to compare tenofovir with other nucleos(t)ide 
analogues using direct and indirect RCT evidence.
Two RCTs compared tenofovir with adefovir (one 
in HBeAg-positive patients, one in HBeAg-negative 
patients), and a third RCT compared tenofovir 
with tenofovir plus emtricitabine. The latter RCT 
was considered by the ERG to be beyond the 
scope of the appraisal and not considered further. 
The primary outcome, ‘complete response’, was a 
composite end point defined as histology response 
(greater than two-point Knodell necroinflammatory 
score without worsening in fibrosis) and HBV DNA 
below 400 copies/ml. For both HBeAg-positive and 
HBeAg-negative patients, a significantly greater 
proportion had a complete response after 48 weeks 
with tenofovir than with adefovir. There was no 
statistically significant difference in histological 
response in either group of patients compared with 
adefovir.
In both HBeAg-positive and HBeAg-negative 
patients, significantly more patients receiving 
tenofovir than adefovir had reductions in HBV 
DNA levels below 400, 300 and 169 copies/ml, 
and the mean reduction from baseline in plasma 
HBV DNA was significantly greater with tenofovir 
than adefovir. There were statistically significant 
differences between tenofovir and adefovir in ALT 
response (although no difference in the proportion 
of HBeAg-negative patients with normalised 
ALT levels at 48 weeks). A similar proportion of 
HBeAg-positive patients experienced HBeAg loss 
and seroconversion at week 48 in the tenofovir 
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and adefovir groups. No HBeAg-negative patients 
experienced HBsAg loss or seroconverted to 
anti-hepatitis B surface antibody (HBs) by week 
48. Significantly more HBeAg-positive patients 
achieved HBsAg loss at 48 weeks with tenofovir 
than with adefovir. No cases of virologic HBV 
resistance have been identified.
There were no statistically significant differences 
between tenofovir and adefovir in overall adverse 
events in either group of patients although, in 
HBeAg-positive patients, there was a greater 
incidence of study drug-related adverse events with 
tenofovir. The manufacturer’s submission attributes 
this to a higher incidence of mild nausea in the 
tenofovir treatment group. The most common 
adverse events were headache, nasopharyngitis, 
back pain, nausea, fatigue and abdominal pain.
An MTC was conducted on two outcomes: the 
probability of HBeAg seroconversion and the 
probability of achieving HBV DNA of less than 300 
copies/ml after 1 year of treatment.
Of four subgroups considered, results could only be 
generated for HBeAg-positive nucleos(t)ide naive 
patients (13 RCTs). There was insufficient RCT 
evidence to construct an MTC for HBeAg-negative 
nucleos(t)ide naive patients, or HBeAg-positive or 
HBeAg-negative lamivudine refractory patients.
The probability of achieving undetectable HBV 
DNA with tenofovir was found to be significantly 
higher than that for all other comparators 
considered in the analysis at the 0.05 level. 
The analysis demonstrated that there is a 98% 
probability that tenofovir is the most potent 
nucleos(t)ide in terms of this outcome. All 
nucleos(t)ides were associated with a significantly 
higher chance of achieving undetectable HBV DNA 
than placebo. Tenofovir, entecavir and telbivudine 
were also found to be significantly superior to 
lamivudine at the 0.05 level.
All treatments other than telbivudine plus 
lamivudine in combination were found to 
significantly increase the probability of HBeAg 
seroconversion at 1 year relative to placebo at 
the 0.05 level. However, this analysis identified 
no statistically significant differences between the 
nucleos(t)ides for this outcome.
Summary of submitted cost-
effectiveness evidence
The manufacturer’s cost-effectiveness analysis 
adopted a Markov state transition model to 
estimate the incremental costs and consequences 
of a range of treatment strategies that include 
tenofovir and other antiviral drugs. Evidence on 
the efficacy of tenofovir, lamivudine, adefovir 
and entecavir (alone or in combination, when 
appropriate) in terms of reducing viral load 
and HBeAg seroconversion were taken from the 
MTC which also estimated baseline outcomes for 
best supportive care (BSC) (based on outcomes 
in the placebo arms of included RCTs). These 
outcomes are associated with reduced probability of 
progression to advanced liver disease and may also 
be associated with improved quality of life.
The model was used to simulate cohorts of patients 
with HBeAg-positive and HBeAg-negative CHB, 
at treatment initiation, separately. The model 
was structured to allow HBeAg-negative CHB to 
emerge in HBeAg-positive patients, following 
reactivation of disease in patients who had achieved 
HBeAg seroconversion. In all other respects the 
model was structurally similar to those adopted for 
previous economic evaluations, including that used 
in the previous NICE assessment of adefovir for the 
treatment of CHB.
The model adopted a lifetime horizon and was 
used to extrapolate lifetime costs and quality-
adjusted life-years (QALYs) for patients treated 
with tenofovir (alone or in combination) and each 
of the included comparators. The analysis assumed 
that once patients develop resistance to their 
current antiviral drug, they will either switch to a 
new drug or add a new drug to their treatment. 
The model was used to evaluate single-agent and 
combination therapies adopted as first-, second- or 
third-line treatment, with BSC retained as the final 
treatment option for patients who have developed 
resistance to all antiviral agents available in each 
treatment strategy. Of the 211 treatment strategies 
evaluated (including BSC) cost-effective strategies 
were selected using the cost-effectiveness frontier 
and incremental cost-effectiveness ratios (ICERs) 
calculated against the next best alternative.
The manufacturer’s submission concluded that 
tenofovir is a cost-effective option as first-line 
treatment. For HBeAg-positive patients, tenofovir 
followed by lamivudine has an ICER of £9940 per 
QALY gained, compared with lamivudine followed 
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by tenofovir. This implied switching treatments 
on development of resistance to first-line therapy, 
which is not supported by clinical guidelines as an 
appropriate clinical strategy. A more appropriate 
treatment strategy of tenofovir followed by 
tenofovir plus lamivudine had an ICER of £13,619 
(incorrectly reported in the manufacturer’s 
submission as £10,055 which is the ICER for 
tenofovir followed by tenofovir plus lamivudine, 
compared with lamivudine followed by tenofovir) 
per QALY gained, compared with lamivudine 
followed by tenofovir.
The manufacturer’s submission reported that 
for HBeAg-negative patients, tenofovir followed 
by lamivudine had an ICER of £9811 per QALY 
gained, compared with BSC. A more clinically 
appropriate treatment strategy of tenofovir 
followed by tenofovir plus lamivudine had an 
ICER of £13,854 per QALY gained, compared with 
tenofovir followed by lamivudine.
In the ERG base-case analysis, amended to correct 
for errors in the manufacturer’s model, these 
ICERs approximately doubled.
Commentary on the robustness 
of submitted evidence
Strengths
The two tenofovir RCTs were of good 
methodological quality and measured outcomes 
that are appropriate and clinically relevant, 
although health-related quality of life was not 
reported. The manufacturer’s submission provided 
a detailed account of their procedures for the 
MTC, although much of this is reported in an 
academic-in-confidence appendix.
The economic model is structurally consistent with 
models adopted for previous economic evaluations. 
The manufacturer’s submission reported that the 
structure of the model was discussed with clinicians 
with relevant expertise. The methods used to 
derive input data for the economic model are 
generally appropriate using published data that, 
for the MTC and pooled analysis of resistance, are 
clearly identified.
The model is appropriately structured to 
incorporate resistance to antiviral agents, and to 
maintain patients’ history of resistance to agents 
within a given treatment strategy.
Weaknesses
The manufacturer’s submission conducted a 
systematic search for clinical effectiveness and cost-
effectiveness studies of tenofovir and comparator 
treatments for CHB. However, some of NICE’s 
recommended databases were not searched, and 
the search is only current to August 2007. ERG 
replication of the searches (PubMed only) from 
August 2007 to December 2008 has not identified 
any additional tenofovir RCTs.
Whilst considered generally sound in terms of 
structure, the MTC suffers from certain limitations, 
including small numbers of studies/single studies 
in some networks, no quality assessment of the 
included studies and no discussion of potential 
clinical heterogeneity.
The ERG uncovered a number of errors in the 
submission. These include transcription errors 
(from the model into the written submission) 
and errors in calculations in the model. Where 
possible the ERG has corrected them and rerun 
the analyses. However, some of the errors would 
require substantial rewriting of the model. The 
ERG has attempted to identify where errors are 
likely to bias the outcome of the evaluation.
The reporting of pre-model analyses is poor, 
particularly in terms of searching for and critical 
appraisal of studies used to estimate parameter 
inputs. In many cases, very limited information is 
provided on studies contributing data to key input 
parameters in the model. There is generally little 
evidence of systematic searches for data to estimate 
parameters, and no critical appraisal of the scope, 
quality or appropriateness of included studies.
Conclusions
Tenofovir is one of a growing number of treatment 
options for patients with CHB. The manufacturer 
has provided a reasonably sound assessment of its 
clinical effectiveness based on two pivotal RCTs in 
HBeAg-positive and -negative nucleos(t)ide naive 
patients, albeit with some limitations.
Tenofovir was statistically significantly superior 
to adefovir for the primary composite outcome 
of HBV DNA response (400 copies/ml) and 
histological response. There were also statistically 
significant differences between the two drugs in 
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terms of secondary outcomes HBV DNA response 
(400 copies/ml) and ALT (HBeAg-positive 
patients only). However, there were no statistically 
significant differences for histology and HBeAg 
seroconversion. Tenofovir was generally well 
tolerated and adverse effects were generally similar 
to adefovir.
Clinical effectiveness data beyond 1 year are 
observational and should be interpreted with 
caution.
Tenofovir appears to have a favourable resistance 
profile based on limited data currently available. 
Whether this will be maintained with long-term 
treatment is yet to be established. These data will 
be important to guide decisions as to whether 
to initiate treatment with monotherapy or 
combination therapy. If resistance in the long-term 
is low, clinicians may decide to initiate treatment 
with tenofovir monotherapy, thus reserving other 
nucleos(t)ides as future treatment options if 
necessary. If resistance to tenofovir monotherapy 
is likely to be high then a clinically plausible 
combination of nucleos(t)ides (e.g. lamivudine and 
tenofovir) may be preferable in order to suppress 
the selection of resistant strains. However, there 
is currently a lack of RCT data for the clinical 
effectiveness of tenofovir in combination with other 
nucleos(t)ides.
There is a lack of head-to-head RCTs comparing 
tenofovir with other nucleos(t)ides, necessitating 
the production of an MTC. The results suggest 
that tenofovir has the highest probability of HBV 
DNA lower than 300 copies/ml response at 1 year 
of treatment. There were no statistically significant 
differences between the nucleos(t)ides in terms of 
HBeAg seroconversion.
The MTC is subject to certain methodological 
limitations, and it was not possible to conduct one 
for HBeAg-negative nucleos(t)ide naive patients, or 
lamivudine refractory patients.
The methods adopted for the economic evaluation 
were reasonable and generally appropriate. The 
model structure was consistent with previous 
economic evaluations. It was appropriately 
structured to incorporate resistance to antiviral 
agents and maintain a history of patients 
developing resistance to agents included in the 
treatment strategy. However, the reporting of pre-
model analyses used to estimate parameter inputs 
was poor, with limited information on studies 
contributing data to key input parameters in the 
model, no evidence of systematic searches for data 
to estimate parameters and no critical appraisal of 
the scope, quality or appropriateness of included 
studies.
A number of errors were detected in the 
submission, including a serious error in the way 
in which QALY outcomes were discounted in the 
electronic model, which affected the deterministic 
(base-case and sensitivity/scenario analyses) and 
the probabilistic analyses. When possible, corrected 
analyses were presented by the ERG. Once the 
identified errors had been corrected and more 
appropriate estimates of uncertainty had been 
incorporated in the analysis, the ERG felt the 
model provided a reasonable characterisation 
of the cost-effectiveness of treatment strategies 
containing tenofovir, in the treatment of CHB.
Areas of uncertainty
There is a lack of head-to-head RCT evidence for 
the clinical effectiveness of tenofovir compared 
to other nucleos(t)ides. It was only possible to 
construct an MTC, taking into account direct 
and indirect RCT evidence, for HBeAg-positive 
treatment naive patients.
Key issues
Tenofovir monotherapy has a favourable resistance 
profile, based on currently available evidence. 
Long-term resistance data are awaited, and 
when available will guide decisions regarding 
whether monotherapy or combination therapy 
should be given. Further RCT data on the clinical 
effectiveness of nucleos(t)ide combination therapy 
are needed to support such decisions.
Summary of NICE guidance 
issued as a result of the STA
The NICE Appraisal Committee met on 11 
February 2009 to discuss this topic. The guidance 
issued by NICE on 22 July 2009 states that: 
Tenofovir disproxil, within its marketing 
authorisation is recommended as an option for the 
treatment of people with chronic HBe-Ag-positive 
or HBe-Ag-negative hepatitis B in whom antiviral 
treatment is indicated.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of prasugrel 
for the treatment of coronary artery syndromes 
with percutaneous coronary intervention, based 
upon the evidence submission from Eli Lilly to 
the National Institute for Health and Clinical 
Excellence (NICE) as part of the single technology 
appraisal process. The submitted clinical evidence 
was based on a phase III double-blind, double-
dummy randomised controlled trial which 
compared the use of prasugrel with clopidogrel. 
The primary clinical outcome measure was a 
composite end point of death from cardiovascular 
causes, non-fatal myocardial infarction (MI) or 
non-fatal stroke at 15 months. Secondary outcomes 
included the primary end point at 30 days and 
90 days; a composite end point of death from 
cardiovascular causes, non-fatal MI or urgent 
target vessel revascularisation; a composite end 
point of death from cardiovascular causes, non-
fatal MI, non-fatal stroke or rehospitalisation 
due to a cardiac ischaemic event; and stent 
thrombosis. For the overall trial cohort during 
the 15 month follow-up period, the results of the 
trial demonstrated a statistically significant benefit 
of prasugrel compared with clopidogrel on the 
primary outcome. The efficacy difference between 
treatment groups was, in the main, due to a 
statistically significant lower incidence of non-fatal 
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MIs in the prasugrel group than in the clopidogrel 
group. No statistically significant differences were 
found for death from cardiovascular causes or 
non-fatal stroke. For the fully licensed and target 
populations, there was a statistically significant 
lower incidence of non-fatal MIs in the prasugrel 
group than in the clopidogrel group; there was 
no statistically significant difference in bleeding 
rates. The ERG recalculated the base-case cost-
effectiveness results taking changes in parameters 
and assumptions into account: for example, 
revised drug costs, mid-cycle correction, amended 
relative risk mortality. Subgroup and threshold 
analyses were also explored by the ERG. For the 
fully licensed population (i.e. excluding patients 
with prior stroke or TIA), the manufacturer 
reported an incremental cost-effectiveness ratio 
(ICER) of £159,358 per quality-adjusted life-year 
(QALY) gained at 12 months and an ICER of 
£3,220 per QALY gained at 40 years. Considering 
the 15-month clinical trial data available for the 
fully licensed and target populations and current 
practice in England and Wales, the evidence was 
considered insufficient to support the conclusion 
that prasugrel is clinically more effective than 
clopidogrel or vice versa. Assuming that there is 
no evidence to distinguish between prasugrel and 
clopidogrel in terms of clinical effectiveness in the 
short term for this population, equipoise between 
prasugrel and clopidogrel at year 1 is achieved by a 
20% reduction in the acquisition cost of prasugrel 
(approximately £120 per patient). At the time of 
writing, the guidance/has not yet been published by 
NICE.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, where most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
entitled ‘Prasugrel for the treatment of coronary 
artery syndromes with percutaneous coronary 
intervention’.2
Description of the underlying 
health problem
Acute coronary syndromes (ACS) are life 
threatening conditions comprising clinical 
symptoms associated with acute myocardial 
ischaemia with or without infarction.3 ACS 
represent manifestations of atherosclerosis, which is 
usually precipitated by acute thrombosis, induced 
by a ruptured or eroded atherosclerotic plaque, 
with or without concomitant vasoconstriction, 
causing a sudden and critical reduction in coronary 
blood flow.4
The leading symptom that initiates the diagnostic 
and therapeutic cascade is chest pain, but 
the classification of patients is based on the 
presentation electrocardiogram.4 The presence 
of acute chest pain and persistent ST-segment 
elevation indicates total occlusion of an affected 
coronary artery. Most of these patients will 
ultimately develop ST-segment elevated myocardial 
infarction (STEMI), resulting in necrosis of the 
tissue supplied by that artery. ACS with acute pain 
without ST-segment elevation is classified as either 
unstable angina (UA) or non-ST-segment elevation 
myocardial infarction (NSTEMI).4
Options for the initial management of ACS 
patients include: (1) drug therapy (heparin, 
antiplatelet agents, beta blockers, nitrates, calcium 
channel blockers, thrombolytic agents and statins) 
or (2) drug therapy in combination with an early 
invasive strategy with percutaneous coronary 
intervention (PCI) (with or without coronary 
stenting) or coronary artery bypass grafting 
(CABG). PCI with coronary stenting is endorsed 
as an early invasive treatment for intermediate to 
high risk patients with ACS.4,5
Approximately 15% of the UK ACS population 
is treated with PCI. In 2007, within the 250,000 
patients diagnosed with ACS, 77,373 PCIs were 
performed. Of these, 40.48% were patients with 
UA/NSTEMI and 13.24% were patients with 
STEMI. Most of the remaining patients (45.10%) 
had stable disease.6
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Scope of the evidence 
review group report
Prasugrel is licensed in Europe to be co-
administered with aspirin for the prevention of 
atherothrombotic events in patients with ACS 
undergoing primary or delayed PCI. The use of 
prasugrel in patients with a history of stroke or 
transitory ischaemic attack (TIA) is contraindicated 
in the Special Product Characteristics, whilst 
use of prasugrel in lighter (less than 60 kg) and 
older (75 years or more) patients is generally not 
recommended.
The ERG report presents the results of the 
evaluation of the manufacturer (Eli Lilly) evidence 
submission regarding the use of prasugrel with 
patients with ACS who are to be managed with 
PCI. The report includes an assessment of both 
the clinical effectiveness and cost-effectiveness 
evidence submitted by the manufacturer. The 
manufacturer submission described the use of 
prasugrel in combination with aspirin compared 
with clopidogrel in combination with aspirin.
The primary clinical outcome measure was a 
composite end point of death from cardiovascular 
causes, non-fatal myocardial infarction (MI) or 
non-fatal stroke at 15 months. Secondary outcomes 
included the primary end point at 30 days and 
90 days; a composite end point of death from 
cardiovascular causes, non-fatal MI or urgent target 
vessel revascularisation; a composite end point 
of death from cardiovascular causes, non-fatal 
MI, non-fatal stroke or rehospitalisation due to 
a cardiac ischaemic event; and stent thrombosis. 
Safety end points included non-CABG-related 
thrombolysis in MI (TIMI) major bleeding, TIMI 
life threatening and TIMI minor bleeding. Health-
related quality of life (HRQoL) was also measured.
An additional outcome measure of net clinical 
benefit comprising a composite end point of death 
from any cause, non-fatal MI, non-fatal stroke, or 
non-CABG-related non-fatal TIMI major bleeding 
was calculated.
Cost-effectiveness was measured in terms of 
incremental cost-effectiveness ratios (ICERs) per 
quality-adjusted life-year (QALY) gained.
Data for a number of different patient populations 
were presented:
• overall trial cohort including stroke or TIA 
(n = 13,608)
• all the ACS licensed population excluding 
prior stroke or TIA (n = 13,090)
• ACS 10-mg licensed population excluding 
prior stroke or TIA (target population) 
(n = 10,941)
• UA/NSTEMI licensed population excluding 
prior stroke or TIA (n = 9669)
• STEMI licensed population excluding prior 
stroke or TIA (n = 3421)
• ACS licensed population excluding prior stroke 
or TIA with diabetes (n = 2947)
• ACS licensed population excluding prior stroke 
or TIA without diabetes (n = 10,143).
Methods
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s submission to NICE as part of the 
STA process.
The ERG evaluated the quality of the 
manufacturer’s clinical effectiveness review. 
Searches conducted by the manufacturer were 
assessed for completeness, and the single trial put 
forward as evidence of effectiveness was critically 
appraised using the manufacturer’s responses 
to specific questions in the submission template. 
With regard to cost-effectiveness evidence, the 
ERG assessed the manufacturer’s searches for 
completeness, critically appraised the submitted 
economic model using a standard assessment 
tool7 and conducted a detailed evaluation of the 
model. The ERG recalculated the base-case cost-
effectiveness results taking changes in parameters 
and assumptions into account: for example, revised 
drug costs, mid-cycle correction, amended relative 
risk mortality. Subgroup and threshold analyses 
were also explored by the ERG.
Results
Summary of submitted 
clinical evidence
The clinical effectiveness evidence was derived 
from a phase III double-blind, double-dummy 
randomised controlled trial (RCT) which compared 
the use of prasugrel with clopidogrel. The TRial 
to Assess Improvement in Therapeutic Outcomes 
by Optimizing Platelet InhibitioN with Prasugrel 
(TRITON)–TIMI 38 was conducted in 30 
countries and included 13,608 patients. For the 
overall trial cohort during the 15 month follow-
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up period, the results of the �TRITON–TIMI 
38 trial demonstrated a statistically significant 
benefit of prasugrel compared with clopidogrel on 
the primary outcome (a composite end point of 
death from cardiovascular causes, non-fatal MI or 
non-fatal stroke). The efficacy difference between 
treatment groups was, in the main, due to a 
statistically significant lower incidence of non-fatal 
MIs in the prasugrel group than in the clopidogrel 
group. No statistically significant differences 
were found for death from cardiovascular causes 
or non-fatal stroke. The trial results reported a 
benefit for prasugrel in the overall trial cohort 
for the majority of secondary end points with 
the exception of death from any cause, where no 
statistical difference was identified. The results are 
summarised in Table 1. In the trial, HRQoL data 
were limited as this substudy comprised responses 
from too few patients. In the overall trial cohort, 
statistically significantly more bleeding events 
occurred in patients in the prasugrel arm than in 
those in the clopidogrel arm. The analysis of the 
pre-specified net clinical benefit outcome (death 
from any cause, non-fatal MI, non-fatal stroke, 
or non-CABG-related non-fatal TIMI major 
bleeding) favoured the use of prasugrel in the 
overall trial cohort. For the fully licensed and target 
populations, there was a statistically significant 
lower incidence of non-fatal MIs in the prasugrel 
group than in the clopidogrel group; there was no 
statistically significant difference in bleeding rates.
Summary of submitted cost-
effectiveness evidence
In the absence of UK-based economic evaluations 
of prasugrel for patients with ACS undergoing 
PCI, the manufacturer conducted a de novo 
economic evaluation. The analysis described in the 
manufacturer submission used a Markov model 
structure with cohorts of patients modelled to 
experience events over the course of the TRITON–
TIMI 38 study period with long-term mortality 
based on adjustment of population life tables 
TABLE 1 TRITON–TIMI 38: Efficacy results at 15 months (overall cohort) 
End point
Prasugrel 
(n = 6813)
Clopidogrel 
(n = 6795)
HR (95% CI) p-valuean (%) n (%)
Primary
Death from CV causes, non-fatal MI or 
nonfatal stroke
643 (9.9) 781 (12.1) 0.81 (0.73 to 0.90) < 0.001
Death from CV causes 133 (2.1) 150 (2.4) 0.89 (0.70 to 1.12) 0.31
Non-fatal MI 475 (7.3) 620 (9.5) 0.76 (0.67 to 0.85) < 0.001
Non-fatal stroke 61 (1.0) 60 (1.0) 1.02 (0.71 to 1.45) 0.93
Secondary
Death from any cause 188 (3.0) 197 (3.2) 0.95 (0.78 to 1.16) 0.64
Death from CV causes, nonfatal MI or 
UTVR
652 (10.0) 798 (12.3) 0.81 (0.73 to 0.89) < 0.001
Death from CV causes 133 (2.1) 150 (2.4) 0.89 (0.70 to 1.12) 0.31
Non-fatal MI 475 (7.3) 620 (9.5) 0.76 (0.67 to 0.85) < 0.001
UTVRb 156 (2.5) 233 (3.7) 0.66 (0.54 to 0.81) < 0.001
Stent thrombosisc 68 (1.1) 142 (2.4) 0.48 (0.36 to 0.64) < 0.001
Death from CV causes, nonfatal MI, 
non-fatal stroke or rehospitalisation 
for ischaemia
797 (12.3) 938 (14.6) 0.84 (0.76 to 0.92) < 0.001
CI, confidence interval; CV, cardiovascular; HR, hazard ratio; MI, myocardial infarction; UTVR, urgent target vessel 
revascularisation.
a p-values were calculated using the log-rank test. The analysis for the primary end point used the Gehan–Wilcoxon test 
for which the p-value was less than 0.
b Taken from published paper.8
c Stent thrombosis defined as definite or probable according to the Academic Research Consortium.
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to reflect prognostic implications of the events 
modelled over the short term. The model also 
permitted in-hospital costs to accumulate after the 
end of the trial follow-up period. The model can 
be separated into two distinct phases: (1) the trial-
based period of 15 months and (2) extrapolation 
beyond the trial to a lifetime horizon (40 years). 
The economic evaluation adopts a lifetime horizon 
for the consideration of in-hospital costs and 
benefits and the perspective is that of the UK NHS 
and Personal Social Services.
For the fully licensed population (i.e. excluding 
patients with prior stroke or TIA), the 
manufacturer reported an ICER of £159,358 per 
QALY gained at 12 months and an ICER of £3,220 
per QALY gained at 40 years; the incremental 
QALY gain for prasugrel patients is very small 
(0.001 QALYs and 0.05 QALYs at 12 months and 
40 years respectively). In addition to the main 
results, ICERs for selected subgroups were also 
presented at 40 years. Univariate sensitivity analysis 
was undertaken using a range of parameters. At 40 
years, using the median UA/NSTEMI profile and 
halving the relative risks for all-cause mortality 
increases the ICER to £10,070 per QALY gained; 
varying the relative risk for prasugrel compared 
with clopidogrel in the first 3 days in an attempt 
to explore the preloading of clopidogrel on cost-
effectiveness yielded a maximum ICER for this 
median patient profile of £22,727 per QALY 
gained.
Probabilistic sensitivity analysis was also conducted 
by the manufacturer using median patient profiles. 
At 40 years, the probabilistic sensitivity analyses 
illustrate that prasugrel is likely to be cost-effective 
compared with clopidogrel (around 75%) for 
what would usually be considered low levels of 
willingness to pay (£20,000) for an additional 
QALY; the ICERs were within the cost-effectiveness 
threshold range used by NICE.
Commentary on the robustness 
of submitted evidence
The manufacturer cited evidence from a large 
trial (TRITON–TIMI 38) to support the superior 
clinical effectiveness of prasugrel compared with 
clopidogrel for the treatment of patients with 
ACS managed with PCI. The trial used robust 
randomisation techniques and was suitably 
powered to show a clinical difference in the 
primary efficacy composite end point between 
the treatment groups. Appropriate pre-specified 
subgroup analyses and post hoc exploratory 
analyses were carried out.
There is only one relevant RCT (TRITON–TIMI 
38) that compares prasugrel versus clopidogrel 
with PCI. The clinical superiority of prasugrel 
over clopidogrel on the primary efficacy endpoint 
is driven largely by a reduction in non-fatal MI, 
an event recorded clinically (symptomatic) and 
non-clinically (by biomarkers/electrocardiogram 
readings). If the non-clinical MIs were considered 
less important to patients, the resultant clinical 
difference in non-fatal MIs alone may not be 
statistically significant.
The primary efficacy composite end point used in 
the trial may not be appropriate as it fails to meet 
published recommendations. In addition, there is 
limited generalisability of the trial protocol to NHS 
patients in England and Wales due to differences 
in the use of clopidogrel and its current use in UK 
clinical practice. Moreover, the growing trend in 
England and Wales for PCI to be performed via 
radial artery access is not reflected in the trial; 
there is evidence that when PCI is performed 
radially, major bleeding rates are reduced. The 
HRQoL trial data were limited as the quality of 
life substudy recruited too few patients to allow 
meaningful analysis of responses.
The economic model described in the 
manufacturer submission made use of a large 
quantity of individual patient data allowing the 
heterogeneity of different patient groups to be 
assessed. The manufacturer asked a clearly defined 
question and attempted to identify, measure and 
value relevant costs and benefits in the economic 
evaluation.
The ERG identified six key areas where corrections 
and/or adjustments to the economic model 
were required: life table calculations to allow 
for competing risks; conventional approach to 
discounting; revised treatment costs reflecting 
actual usage and pack wastage; alternate utility 
values; amended long-term relative risks of 
mortality; and reduced incidence of non-fatal 
recurrent MIs. Taken together, these corrections 
and/or adjustments have increased the size of the 
ICER for all patient populations (Table 2).
The methods used to project outcomes and costs 
after the trial period are crucial to the acceptance 
or rejection of the manufacturer’s ICER. The ERG 
advises caution in view of the various problems that 
are apparent with this part of the submitted model. 
If the ERG had been able to modify some of the 
model’s underlying assumptions, then it is likely 
that the magnitude of the re-estimated ICER would 
be increased further.
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Conclusions
Considering the 15-month clinical trial data 
available for the fully licensed (i.e. excluding 
prior stroke or TIA) and target populations 
(i.e. excluding prior stroke or TIA, and patients 
weighing less than 60 kg or aged 75 years or older) 
and current practice in England and Wales, the 
evidence was considered insufficient to support the 
conclusion that prasugrel is clinically more effective 
than clopidogrel or vice versa.
Assuming that there is no evidence to distinguish 
between prasugrel and clopidogrel in terms 
of clinical effectiveness in the short term for 
this population, equipoise between prasugrel 
and clopidogrel at year 1 is achieved by a 20% 
reduction in the acquisition cost of prasugrel 
(approximately £120 per patient).
The modelled net health benefits (QALYs) do not 
achieve positive gains for prasugrel until more than 
10 years’ follow-up has elapsed, except for patients 
with diabetes mellitus. The ERG considered that 
the submitted evidence from long-term projection 
(at 40 years) is not sufficiently robust to support 
the conclusion that prasugrel is more cost-effective 
than clopidogrel for the fully licensed population.
Given that the trial evidence appears to show that 
prasugrel and clopidogrel yield similar overall 
health benefits in the short-term, it could be 
argued that, at an equivalent net cost per patient, 
prasugrel might represent a viable alternative.
Summary of NICE guidance 
issued as a result of the STA
The guidance issued by NICE in October 2009 
states that: 
1.1 Prasugrel in combination with aspirin is 
recommended as an option for preventing 
atherothrombotic events in people with acute 
coronary syndromes having percutaneous 
coronary intervention, only when:
• immediate primary percutaneous coronary 
intervention for ST-segment-elevation 
myocardial infarction is necessary or 
• stent thrombosis has occurred during 
clopidogrel treatment or 
• the patient has diabetes mellitus.
1.2 People currently receiving prasugrel for 
treatment of acute coronary syndromes whose 
circumstances do not meet the criteria in 1.1 
should have the option to continue therapy 
until they and their clinicians consider it 
appropriate to stop.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of alitretinoin 
for the treatment of adults with severe chronic 
hand eczema refractory to topical steroid treatment 
in accordance with the licensed indication, based 
upon the evidence submission from Basilea 
Pharmaceuticals Ltd to the National Institute for 
Health and Clinical Excellence (NICE) as part 
of the single technology appraisal process. The 
clinical evidence came from a single placebo-
controlled randomised controlled trial of daily 
treatment with alitretinoin for 12–24 weeks, with 
follow-up for a further 24 weeks, in patients with 
severe chronic hand eczema (CHE) unresponsive 
to topical steroids. A statistically significantly 
greater proportion of patients using alitretinoin 
achieved the primary end point of clear or 
almost clear hands by week 24 than did those 
with placebo. Dose-dependent headache was 
the most commonly reported adverse event in 
patients treated with alitretinoin. Serious adverse 
events were rare, but alitretinoin was associated 
with increases in both total cholesterol and 
triglycerides, which has implications for risks of 
future cardiovascular events. The manufacturer 
submitted a de novo decision analytic model 
to estimate, over a time horizon of 3 years, the 
cost-effectiveness of alitretinoin versus the other 
relevant comparators identified by NICE. In 
response to the points of clarification put to it 
by the ERG regarding the initial submission, 
the manufacturer provided additional evidence 
and a revised decision analytic model with a 
‘placebo’ arm. In the manufacturer’s original 
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submission to NICE, the base-case incremental 
cost-effectiveness ratios (ICERs) reported for 
alitretinoin were £8614 per quality-adjusted life-
year (QALY) versus ciclosporin, –£469 per QALY 
versus psoralen + UVA (with alitretinoin dominant) 
and £10,612 per QALY versus azathioprine. 
These ICERs decreased as the time horizon was 
extended in sensitivity analyses. In patients with 
hyperkeratotic CHE and in women of child-bearing 
potential, the ICER remained below £20,000. 
When the health-related quality of life (HRQoL) 
values used in the model were replaced with those 
derived from an alternative study, these ICERs 
increased significantly (to £22,312 per QALY for 
alitretinoin versus azathioprine). In the revised 
model, alitretinoin was reported to have an ICER 
of £12,931 per QALY gained versus supportive 
care (placebo). However, the model underestimates 
the costs of treatment associated with alitretinoin. 
The manufacturer assumed that patients receiving 
alitretinoin visited the dermatologist every 4 weeks 
and ceased treatment as soon as they responded to 
it. If, in practice, patients would receive treatment 
for longer than this, then the manufacturer’s model 
will have significantly underestimated the costs to 
the NHS. Additional analyses undertaken by the 
ERG produced ICERs close to £30,000 per QALY 
gained for alitretinoin versus supportive care. 
This was largely due to uncertainty surrounding 
the impact of alitretinoin on HRQoL. The 
placebo-controlled trials conducted to date have 
established that alitretinoin can be efficacious for 
the treatment of severe CHE refractory to topical 
steroids, but longer term follow-up of trials or 
the implementation of registries is required to 
better establish the longer term efficacy or safety 
of alitretinoin. NICE recommended the use of 
alitretinoin for patients with severe CHE and a 
Dermatology Life Quality Index (DLQI) score 
of at least 15. Treatment was recommended to 
be stopped as soon as an adequate response was 
observed, or if CHE remained severe at 12 weeks, 
or if response was inadequate at 24 weeks.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, where most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG); an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
entitled ‘Alitretinoin for the treatment of severe 
chronic hand eczema’.2
Description of the underlying 
health problem
It is estimated that between 0.5% and 0.7% of the 
general population suffer from severe chronic 
hand eczema (CHE).3 Management of hand 
eczema includes avoidance of allergens and 
irritants, skin protection measures and use of 
topical corticosteroids where necessary. Patients 
with chronic disease may require treatment with 
the most potent steroid preparations available 
because drug penetration is impaired by significant 
hyperkeratosis of the hands. Approximately 50% 
of affected patients will be refractory to treatment 
with topical corticosteroids.3 These patients 
suffer from painful cracks and blisters susceptible 
to secondary infections, itching and bleeding, 
which can limit manual dexterity and prevent 
employment. The visibility of disease, need for 
frequent visits to the doctor and regular application 
of greasy topical agents, all add to the burden of 
the disease. Severe CHE carries a debilitating social 
stigma which is associated with an impaired quality 
of life, comparable to that seen in patients with 
generalised eczema and psoriasis.4 In addition, 
hand eczema has been shown to be a major cause 
of prolonged sick leave and has been reported to 
lead to job loss.5 Patients with CHE have a poor 
prognosis; it is a self-perpetuating condition with a 
long-lasting and chronically relapsing course.6 No 
licensed treatment options are available for these 
patients. The unlicensed options used in clinical 
practice include immunosuppressants, such as 
ciclosporin and azathioprine, and phototherapy.
Scope of the evidence 
review group report
Oral alitretinoin (9-cis-retinoic acid, Toctino®), 
an endogenous retinoid, is indicated for use in 
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adults who have severe chronic hand eczema that 
is unresponsive to treatment with potent topical 
corticosteroids. The recommended dose range for 
alitretinoin is 10–30 mg once daily. A treatment 
course of alitretinoin should be started at the 
higher dose of 30 mg and may be given for 12–24 
weeks depending on response. Discontinuation 
of therapy should be considered for patients who 
still have severe disease after the initial 12 weeks of 
treatment.
The ERG report presents an assessment of the 
manufacturer’s (Basilea Pharmaceuticals Ltd) 
submission to NICE on the use of alitretinoin 
(within the context of the licensed indication) in 
adults with severe chronic hand eczema refractory 
to topical steroid treatment and attempted 
to compare it with the stated comparators: 
psoralen + UVA (PUVA), ciclosporin and 
azathioprine.
Evidence for the efficacy of alitretinoin came 
primarily from a phase III randomised placebo-
controlled double-blinded trial and an extension 
study.7,8 The primary report outcome was ‘clear’ or 
‘almost clear’ hands as assessed by the physician’s 
global assessment (PGA). Other outcomes reported 
included signs and symptoms of the disease, as 
measured by the modified Total Lesion Symptom 
Score (mTLSS), the patient global assessment 
(PaGA) of disease severity, and adverse events.
The manufacturer developed a de novo decision 
analytic model to estimate, over a time horizon of 
3 years, the cost-effectiveness of alitretinoin versus 
the other relevant comparators identified by NICE. 
In response to the points of clarification put to 
them by the ERG regarding the initial submission, 
the manufacturer provided additional evidence 
and a revised decision analytic model. The model 
estimated costs and quality-adjusted life-years 
(QALYs) from the perspective of the NHS and 
Personal Social Services (PSS), which is consistent 
with NICE guidelines.
Methods
The ERG report comprised a critical review of 
the evidence for the clinical evidence and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process.
As well as a detailed critical appraisal of the 
manufacturer’s submission, the ERG completed 
searches of its own to take into account some of 
the issues raised in its review of the manufacturer’s 
search strategies and also modified the 
manufacturer’s decision analytic model to examine 
the impact of altering some of the key assumptions.
Results
Summary of submitted 
clinical evidence
The main clinical effectiveness data were derived 
from a single placebo-controlled randomised 
controlled trial (RCT) of daily treatment with 
alitretinoin for 12–24 weeks (BAP00089), with 
follow-up for a further 24 weeks, in patients with 
severe CHE unresponsive to topical steroids. 
In this study, a statistically significantly greater 
proportion of patients using alitretinoin achieved 
the primary end point of clear or almost clear 
hands (as assessed by the PGA) by week 24 than 
did those with placebo: 48% with alitretinoin 30 mg 
(p < 0.001); 28% with alitretinoin 10 mg (p < 0.005); 
16.6% with placebo. The severity of disease was 
also reduced when assessed by patients using the 
PaGA. The majority of patients who responded 
to alitretinoin treatment remained in remission 
during the 24-week follow-up period. A high PGA 
response rate to retreatment with alitretinoin was 
observed, although a similarly high response to 
placebo was observed among first-line ‘placebo 
responders’, and PGA results were not consistent 
with the PaGA evaluations. The main effectiveness 
data from all reported trials are presented in 
Table 1.
Dose-dependent headache was the most commonly 
reported adverse event in patients treated with 
alitretinoin, with rates of 20% in the alitretinoin 
30-mg group and 11% in the 10-mg group. Serious 
adverse events were rare, but alitretinoin was 
associated with increases in both total cholesterol 
and triglycerides, which has implications for risks 
of future cardiovascular events.
No direct comparisons of alitretinoin with any 
of the relevant treatment comparators (PUVA, 
ciclosporin or azathioprine) were available. 
Nor were any trial data on these comparators 
available to permit formal indirect comparisons of 
alitretinoin with its comparators.
Summary of submitted cost-
effectiveness evidence
The manufacturer submitted a de novo decision 
analytic model to estimate, over a time horizon of 
3 years, the cost-effectiveness of alitretinoin versus 
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the other relevant comparators identified by NICE. 
In response to the points of clarification put to it 
by the ERG regarding the initial submission, the 
manufacturer provided additional evidence and a 
revised decision analytic model.
In the manufacturer’s original submission to NICE, 
the base-case incremental cost-effectiveness ratios 
(ICERs) reported for alitretinoin were £8614 per 
QALY versus ciclosporin, –£469 per QALY versus 
PUVA (with alitretinoin dominant) and £10,612 
per QALY versus azathioprine. These ICERs 
TABLE 1 Primary and secondary study end points from controlled trials included in manufacturer’s submission 
Trial Treatment
Response: PGAa 
(95% CI)
Response: 
PaGAa
Symptom 
change: mTLSSb 
(95% CI)
Health-
related 
quality of 
life: DLQIc
Relapse 
rated
BAP00089 Placebo 16.6% (11.8 to 22.4) 15% –39% (–47 to –27)
10 mg 27.5% (23.3 to 32.1), 
p < 0.005e
24%, p < 0.02e –56% (–63 to –50), 
p < 0.001e
29.6% (at 
6 months)
30 mg 47.7% (42.7 to 52.6), 
p < 0.001e
40%, p < 0.001e –75% (–79 to –69), 
p < 0.001e
37.4% (at 
6 months)
BAP00091 
(Cohort A)
Placebo 
(previously 
placebo)
69.2% 23.1% –40.3%
Placebo 
(previously 10 mg)
10%
Placebo 
(previously 30 mg)
8.3%
10 mg 47.6% 75.5% –78.8%, p = 0.02f
30 mg 79.6% 38.1% –67.4%, p < 0.001f
BAP00091 
(Cohort B)
30 mg 46.2% 42.4% –49.7%
BAP00003 Placebo 27% 12% –25% (–42 to –14) –2 26%
10 mg 39%, p = nse 29%, p = 0.014e –59% (–73 to –42), 
p = 0.03e
–2 25%
20 mg 41%, p = nse 34%, p = 0.002e –52% (–73 to –42), 
p = 0.002e
–3 26%
40 mg 53%, p < 0.001e 43%, p < 0.001e –59% (–80 to –44), 
p < 0.001e
–3 32.5%
BAP00200 10 mg 12.5%  
(1.6, to 38.3)
30 mg 62.5%  
(35.4 to 84.8)
CI, confidence interval; DLQI, Dermatology Life Quality Index; mTLSS, modified Total Lesion Symptom Score; ns, not stated; 
PaGA, patient global assessment; PGA, physician’s global assessment.
a Percentage with clear/almost clear hands.
b Median change in mTLSS score from baseline.
c Median within-patient change from baseline to week 12.
d Percentage with mTLSS score 75% of baseline value.
e Compared with placebo.
f Compared with placebo (previously 30 mg).
decreased as the time horizon was extended in 
sensitivity analyses. In patients with hyperkeratotic 
CHE and in women of child-bearing potential, 
the ICER remained below £20,000. When the 
health-related quality of life (HRQoL) values used 
in the model were replaced with those derived 
from an alternative study, these ICERs increased 
significantly (to £22,312 per QALY for alitretinoin 
versus azathioprine). In the revised model, which 
compared alitretinoin only to placebo, the ICER 
was reported to be £12,931.
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Commentary on the robustness 
of submitted evidence
Strengths
The manufacturer’s submission incorporated a full 
systematic review of the literature of the effects 
of alitretinoin in severe CHE refractory to topical 
steroid treatment. The main findings are derived 
from a single generally well-conducted placebo-
controlled RCT and an associated follow-up trial of 
retreatment.
The submission also included a review of the 
literature of the cost-effectiveness of alitretinoin in 
severe CHE. As no existing economic evaluations 
were identified, the manufacturer undertook a de 
novo economic evaluation in order to compare 
alitretinoin with comparators identified by NICE, 
consisting of ciclosporin, PUVA and azathioprine. 
The model estimated costs and QALYs from 
the perspective of the NHS and PSS, which is 
consistent with NICE guidelines.
Weaknesses
At present, there is a relatively limited quantity 
of evidence available on the clinical effects of 
alitretinoin. Although the RCTs presented were 
adequately designed and conducted, the ERG 
noted high numbers of withdrawals from the 
main efficacy trial, a lack of clear evidence for 
the reported subgroup effects and unexplained 
inconsistencies between PGA and PaGA scores in 
the retreatment trial.
Limitations in the submitted evidence primarily 
impacted on the generalisability of the 
manufacturer’s conclusions to clinical practice. The 
main observed effects of alitretinoin were relative to 
placebo with additional emollients where required. 
Therefore it remains unknown to what extent 
alitretinoin is effective relative to emollients and 
topical corticosteroids combined (the current first-
line treatment choice).
For inclusion in the main RCT (BAP00089), 
diagnosis as ‘severe’ on the PGA outcome measure 
was a pre-requisite. In clinical practice, it seems 
likely that a proportion of patients considered 
for treatment with alitretinoin would fall into the 
less severe PGA ‘moderate’ state. There is some 
evidence from the phase II trial BAP00003 that a 
‘PGA moderate’ CHE population would respond to 
alitretinoin treatment, but there is no evidence for 
the effects of the 30 mg dose in this population.
The cost-effectiveness section of the submission 
had major shortcomings. The efficacy estimates for 
treatments other than alitretinoin were based on 
expert clinical opinion only. While the use of expert 
opinion may be justified where trial data do not 
exist to inform the relevant parameters, it should 
be elicited in a methodologically rigorous manner. 
The ERG remains unconvinced that this elicitation 
process generated reliable estimates of the efficacy 
of each of the comparator treatments. The 
estimates of HRQoL were derived in a two-stage 
prediction model that incorporated an algorithm 
developed for patients with psoriasis. Direct 
evidence of the impact of alitretinoin on HRQoL 
was only available from the phase II trial, which did 
not include the recommended 30 mg starting dose 
of alitretinoin and showed no difference between 
alitretinoin (10 mg, 20 mg and 40 mg) and placebo.
Serious issues remain around the implementation 
of the model in excel. Inspection of the VBA 
(Visual Basic for Applications) code indicated that 
a number of the assumptions given in the written 
submission were not implemented correctly. In 
particular, the first 4 weeks of every subsequent 
treatment cycle were omitted. The definition of 
relapse used in the model did not correspond 
to that used in the relevant clinical trials. As 
a consequence the estimated costs and health 
outcomes presented by the manufacturer may be 
regarded as unreliable. The ERG attempted to 
amend the model to provide more appropriate 
estimates of the ICERs, but in some cases this was 
not feasible.
Furthermore, the model originally submitted 
to NICE did not include a ‘supportive care’ (or 
‘placebo’) arm and the treatment effects for 
alitretinoin were not placebo adjusted; as such, 
the model did not address whether alitretinoin 
was a cost-effective alternative to supportive care. 
Consequently, the ERG does not regard the ICERs 
generated by the manufacturer’s original model 
as providing a reliable indication of the cost-
effectiveness of alitretinoin compared with each of 
the comparators considered.
Areas of uncertainty
Crucially, there is no evidence on the efficacy and 
safety of alitretinoin beyond around 48 weeks. 
Given the chronic recurring nature of CHE, longer 
term follow-up is required to detect potentially 
rare adverse events and possibly to characterise the 
cardiovascular risks posed by the observed increase 
in cholesterol levels associated with alitretinoin 
treatment.
There was also no direct or indirect evidence 
presented for the clinical effects of alitretinoin 
relative to the comparators specified in the scope 
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for the treatment of CHE (PUVA, ciclosporin 
and azathioprine). No additional evidence was 
identified by the ERG.
A change in threshold for the definition of ‘relapse’ 
from 75% to 50% of baseline mTLSS substantially 
reduced the time to relapse observed in the 30-mg 
alitretinoin group. If clinicians were to consider 
retreatment for less severe ‘relapses’, this would 
have clinical and cost implications in terms of the 
reduced time between treatment periods.
As the relief of symptoms and consequent 
improvement in HRQoL are the aims of treatment 
for chronic hand eczema, the ERG believes that the 
economic evaluation of alitretinoin should be based 
on good evidence of the improvement in HRQoL 
offered by alitretinoin. However, the estimates 
used in the submission are subject to a great deal 
of uncertainty due to the two-stage prediction 
employed and the paucity of direct observations in 
the population of interest.
The ERG modified the manufacturer’s model to 
examine the impact of altering some of the key 
assumptions. However, as the manufacturer did 
not undertake a probabilistic sensitivity analysis, 
the combined impact of uncertainty in the inputs 
to the economic model on the overall decision 
uncertainty could not be evaluated.
Conclusions
In response to a request from the ERG, the 
manufacturer provided a revised model with a 
‘placebo’ arm, and the comparison of alitretinoin 
with placebo made in this revised model is of 
greater merit given the more reliable efficacy data 
in the comparator arm. In this analysis, alitretinoin 
was reported to have an ICER of £12,931 per 
QALY gained versus supportive care (placebo). 
However, the omission of adverse events from this 
revised model, in combination with a number of 
other factors, means that the model underestimates 
the costs of treatment associated with alitretinoin.
TABLE 2 Results of additional analyses comparing the impact of two alternative health-related quality of life estimates provided by the 
manufacturer
Treatment
BAP0003 utility data Augustin utility data
Cost QALYs
ICER  
(per QALY) Cost QALYs
ICER  
(per QALY)
Analysis 1: Base-case reanalysis
Supportive care £481.40 1.79 £481.40 2.05
Alitretinoin (30 mg) £3369.21 2.01 £13,431.67 £3369.21 2.16 £27,996.89
Analysis 2: Patients relapse into PGA moderate and severe
Supportive care £481.60 1.78 £481.60 2.05
Alitretinoin (30 mg) £3509.33 1.99 £14,525.65 £3509.33 2.15 £29,864.39
Analysis 3a: Potentially child-bearing women only
Supportive care £481.40 1.79 £481.40 2.05
Alitretinoin (30 mg) £3548.95 2.01 £14,267.64 £3548.95 2.16 £29,739.38
Analysis 3b: Men only
Supportive care £481.40 1.79 £481.40 2.05
Alitretinoin (30 mg) £3337.49 2.01 £13,284.14 £3337.49 2.16 £27,689.38
Analysis 4: Reinstate adverse events for alitretinoin only
Supportive care £481.40 1.79 £481.40 2.05
Alitretinoin (30 mg) £3370.37 2.00 £14,072.21 £3370.37 2.15 £29,199.56
ICER, incremental cost-effectiveness ratio; PGA, physician’s global assessment; QALYs, quality-adjusted life-years.
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The manufacturer assumed that patients receiving 
alitretinoin visited the dermatologist every 4 
weeks and ceased treatment as soon as they 
responded to it, even if this was after only 4 or 
8 weeks of treatment. If, in practice, patients 
would receive treatment for longer than this, then 
the manufacturer’s model will have significantly 
underestimated the costs to the NHS.
Additional analyses undertaken by the ERG 
produced ICERs close to £30,000 per QALY gained 
for alitretinoin versus supportive care. This was 
largely due to uncertainty surrounding the impact 
of alitretinoin on HRQoL. Utilising the alternative 
HRQoL estimates identified by the manufacturer 
resulted in a two-fold increase in the ICER (see 
Table 2 for a comparison of the different estimates). 
There remains considerable uncertainty as to 
the true ICER of alitretinoin versus the relevant 
treatment comparators.
Implications for research
Given the limited duration of the available 
evidence, longer term follow-up of trials or the 
implementation of registries may be required 
to better establish the longer term efficacy and 
safety of alitretinoin. The placebo-controlled trials 
conducted to date have established that alitretinoin 
can be efficacious for the treatment of severe CHE 
refractory to topical steroids. However, future 
studies should include a relevant HRQoL measure 
(such as the Dermatology Life Quality Index and 
the European Quality of Life – 5 Dimensions) 
alongside measures of therapeutic response and 
may want to establish the efficacy of alitretinoin 
relative to current first-line treatment (emollients 
plus topical steroids) and other treatments that 
are used in this indication (PUVA, azathioprine, 
ciclosporin).
Summary of NICE guidance 
issued as a result of the STA
The guidance issued by NICE states that:
NICE recommended Alitretinoin as a possible 
treatment for people with severe chronic hand 
eczema if:
• their eczema has not improved with treatments 
called potent topical corticosteroids and
• standard assessments (PGA and DLQI) show 
that their eczema is severe and is affecting their 
quality of life.
Alitretinoin treatment should be stopped:
• as soon as the eczema has clearly improved or
• if the eczema remains severe after 12 weeks or
• if the eczema has not clearly improved after 24 
weeks.
Treatment with alitretinoin should be started and 
monitored only by doctors who:
• are skin specialists (dermatologists) or
• have experience in both treating people with 
severe chronic hand eczema and using drugs 
like alitretinoin.
When assessing how a person’s eczema affects their 
quality of life, healthcare professionals should 
take into account any disabilities or difficulties 
in communicating which might mean that the 
standard assessments do not provide accurate 
information.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of pemetrexed 
for the first-line treatment of locally advanced or 
metastatic non-small cell lung cancer (NSCLC), 
in accordance with the licensed indication, based 
upon the evidence submission from Eli Lilly 
Ltd to the National Institute for Health and 
Clinical Excellence (NICE) as part of the single 
technology appraisal process. The majority of the 
efficacy evidence described in the manufacturer’s 
submission is derived from a phase III open-label 
randomised controlled trial (RCT) known as the 
JMDB trial. The trial achieved its primary objective 
to demonstrate non-inferiority of pemetrexed/
cisplatin to gemcitabine/cisplatin for overall 
survival in all patients with NSCLC. Because no 
other studies were found comparing pemetrexed/
cisplatin with any other relevant comparator, 
additional efficacy evidence was presented from two 
phase III RCTs comparing gemcitabine/cisplatin 
with gemcitabine/carboplatin and docetaxel/
cisplatin. The manufacturer’s submission reported 
from its indirect comparisons’ analysis that median 
overall survival and progression-free survival 
and tumour response rates were more favourable 
for pemetrexed/cisplatin than for any other 
comparator. The manufacturer did not identify any 
published cost-effectiveness analyses of pemetrexed 
for the first-line treatment of patients with NSCLC. 
Therefore economic evidence was derived solely 
from a de novo economic model developed by the 
manufacturer. A Markov model was developed 
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to evaluate the cost-effectiveness of pemetrexed/
cisplatin compared to gemcitabine/cisplatin, 
docetaxel/cisplatin and gemcitabine/carboplatin. 
The clinical data used in the economic evaluation 
were primarily generated from the JMDB trial, 
with additional data from the two further trials 
used in the indirect comparisons analysis. The ERG 
identified a series of problems with this economic 
model. As a result, three different versions of the 
model were submitted to NICE and considered by 
the ERG. The ICERs estimated by this final version 
of the model ranged from £8056 to £33,065 
per QALY, depending on the comparator, the 
population and the application of a continuation 
rule. The ERG considered that the model required 
extensive modification and redesign, and should be 
subjected to thorough validation against the JMDB 
trial results. A full quality audit was also required 
as it was likely that further model inconsistencies 
may be present that had not yet been identified. 
The manufacturer subsequently included evidence 
in the form of three cost effectiveness analyses 
(two models and an ‘in-trial’ analysis), stating that 
a thorough validation process had been followed 
according to the NICE request. The very short 
time available to the ERG to consider the new 
evidence precluded a comprehensive assessment. 
Instead, the ERG chose to present a simple 
exploratory analysis combining its own survival 
projections with key cost estimates obtained from 
the JMDB trial individual patient data. Compared 
to gemcitabine, this resulted in ICERs ranging 
from £17,162 to £30,142 per QALY, depending 
on the patient population, the maximum number 
of cycles of chemotherapy and whether a cycle 
based efficacy adjustment was applied or not. The 
guidance issued by NICE in September 2009 states 
that pemetrexed in combination with cisplatin 
is recommended as an option for the first-line 
treatment of patients with locally advanced or 
metastatic NSCLC only if the histology of the 
tumour has been confirmed as adenocarcinoma or 
large-cell carcinoma.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, where most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG); an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
of pemetrexed for the first-line treatment of locally 
advanced or metastatic non-small cell lung cancer 
(NSCLC).2
Description of the underlying 
health problem
According to Cancer Research UK,3 over 38,000 
people were diagnosed with lung cancer in the 
UK in 2005. Survival from lung cancer is poor 
with around a quarter of patients (25% men, 26% 
women) surviving for 1 year after diagnosis, falling 
to 7% for 5 years after diagnosis, and the disease 
was responsible for approximately 34,000 deaths 
in 2006. Reasons for this poor prognosis include 
the late identification of the disease and low active 
anticancer treatment rates.
The main subtypes of NSCLC are squamous 
cell carcinoma, adenocarcinoma and large-cell 
carcinoma. According to a recent audit of England 
and Wales,4 33% of patients had squamous NSCLC, 
25% had adenocarcinoma, 4% had large-cell 
carcinoma with the remaining 36% defined as 
NSCLC ‘not-otherwise specified’ (NSCLC-NOS).
Scope of the evidence 
review group report
The ERG report presents the results of the 
assessment of the manufacturer’s (Eli Lilly 
Ltd) evidence submission regarding the use of 
pemetrexed with cisplatin compared to platinum-
based chemotherapy for the first-line treatment 
of locally advanced or metastatic NSCLC. The 
report includes an assessment of both the clinical 
effectiveness and cost-effectiveness evidence 
submitted by the manufacturer. The primary 
clinical outcome measure was overall survival 
with secondary outcomes of progression-free 
survival (PFS), response to therapy and tolerability. 
The cost-effectiveness data were presented as 
incremental cost-effectiveness ratios (ICERs).
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Pemetrexed (Alimta®) is a multitargeted anticancer 
antifolate agent that exerts its action by disrupting 
crucial folate-dependent metabolic processes 
essential for cell replication. It was approved by the 
European Commission for the first-line treatment 
of NSCLC (other than predominantly squamous 
cell histology) in combination with cisplatin on 8 
April 2008. In this group of patients, it is indicated 
for patients with locally advanced or metastatic 
NSCLC.
Methods
The ERG report comprised a critical review of 
the evidence for the clinical evidence and cost-
effectiveness of the technology based upon the 
manufacturer’s submission to NICE as part of the 
STA process. The ERG evaluated the quality of 
the manufacturer’s clinical effectiveness review. 
Searches conducted by the manufacturer were 
assessed for completeness, and the single trial put 
forward as evidence of effectiveness5 was critically 
appraised. With regard to cost-effectiveness 
evidence, the ERG assessed the manufacturer’s 
searches for completeness, critically appraised 
the submitted economic model using a standard 
assessment tool (Drummond and Jefferson6) and 
conducted an evaluation of the model.
Results
Summary of submitted 
clinical evidence
The majority of the efficacy evidence described in 
the manufacturer’s submission is derived from a 
phase III open-label randomised controlled trial 
(RCT) known as the JMDB trial5 and is presented 
in Table 1. The trial achieved its primary objective 
to demonstrate non-inferiority of pemetrexed/
cisplatin to gemcitabine/cisplatin for overall 
survival in all patients with NSCLC [median 
10.3 months for both trial arms, adjusted hazard 
ratio (HR) = 0.94; 95% confidence interval (CI) 
0.84 to 1.05]. As pemetrexed is only indicated 
for the first-line treatment of patients with non-
squamous NSCLC, a subgroup analysis of patients 
with non-squamous NSCLC was presented that 
reported superiority of pemetrexed/cisplatin on 
the primary outcome of overall survival compared 
with gemcitabine/cisplatin (median 11.0 and 10.1 
months, respectively, adjusted HR = 0.84; 95% 
CI 0.74 to 0.96). In the population of patients 
with non-squamous NSCLC, median PFS was not 
reported to be statistically superior and, while 
tumour response rates were reported to be higher 
for pemetrexed/cisplatin, significance tests were not 
reported.
The manufacturer also defined a more specific 
target population of patients with adenocarcinoma 
or large-cell carcinoma. In this target population, 
median overall survival was also significantly 
superior in the pemetrexed/cisplatin group 
(median 11.8 and 10.4 months, respectively, 
adjusted HR = 0.81; 95% CI 0.70 to 0.94). It should 
be noted that defining the target population in 
clinical practice would require more specific testing 
than is currently standard practice in the UK (as 
treatment is currently based on whether patients 
have squamous or non-squamous NSCLC). A study 
of preoperative histological classification of lung 
cancer7 cited by the manufacturer suggests that 
diagnosing adenocarcinoma may be particularly 
challenging.
Because no other studies were found comparing 
pemetrexed/cisplatin with any other relevant 
comparator, additional efficacy evidence was 
presented from two phase III RCTs comparing 
gemcitabine/cisplatin with gemcitabine/
carboplatin8 and docetaxel/cisplatin9 (Table 2). 
The manufacturer’s submission reported from its 
indirect comparisons’ analysis that median overall 
survival and PFS and tumour response rates were 
more favourable for pemetrexed/cisplatin than for 
any other comparator.
With the exception of nausea, pemetrexed/cisplatin 
appeared to be more tolerable than gemcitabine/
cisplatin in terms of grade 3/4 toxicities. No 
safety issues related to pemetrexed/cisplatin arose 
beyond those already previously documented. 
No significant differences were reported for 
tolerability regarding the different cisplatin 
regimens (pemetrexed/cisplatin, gemcitabine/
cisplatin and docetaxel/cisplatin). Gemcitabine/
carboplatin reported less non-haematologic 
toxicity in terms of nausea and vomiting, and more 
haematoxicity in terms of an increased incidence of 
thrombocytopenia than gemcitabine/cisplatin.
Summary of submitted cost-
effectiveness evidence
The manufacturer did not identify any published 
cost-effectiveness analyses of pemetrexed for 
the first-line treatment of patients with NSCLC. 
Therefore economic evidence was derived solely 
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TABLE 1 Key efficacy findings in the JMDB trial5 (intention-to-treat analysis)
Patient group
Median (months) (95% CI) or response rate (%)
Adjusted 
HR (95% CI)
p-value 
(superiority)Pemetrexed/Cisplatin Gemcitabine/Cisplatin
Overall survival
All randomised patients 
including squamous NSCLC 
(n = 1725)
10.3  
(9.8 to 11.2)
10.3  
(9.6 to 10.9)
0.94  
(0.84 to 1.05)
p < 0.001a
p = 0.259b
Patients with non-squamous 
histology (n = 1252)
11.0 
(10.1 to 12.5)
10.1 
(9.3 to 10.9)
0.84 
(0.74 to 0.96)
p = 0.011b
Target patients: 
adenocarcinoma or large-
cell carcinoma (n = 1000)
11.8 
(10.4 to 13.2)
10.4 
(9.6 to 11.2)
0.81 
(0.70 to 0.94)
p = 0.005b
Patients with 
adenocarcinoma (n = 847)
12.6 
(10.7 to 13.4)
10.9 
(10.1 to 11.9)
0.84 
(0.71 to 0.99)
p = 0.033b
Patients with large-cell 
carcinoma (n = 153)
10.4 
(8.6 to 14.1)
6.7 
(5.5 to 9.0)
0.67 
(0.48 to 0.96)
p = 0.027b
Patients with NSCLC-NOS 
(n = 252)
8.6 
(6.8 to 10.2)
9.2 
(8.1 to 10.6)
1.08 
(0.81 to 1.45)
p = 0.586b
Progression-free survival
All randomised patients 
including squamous NSCLC 
(n = 1725)
4.8 
(4.6 to 5.3)
5.1 
(4.6 to 5.5)
1.04 
(0.94 to 1.15)
Not reported
Patients with non-squamous 
histology (n = 1252)
5.3 
(4.7 to 5.5)
5.0 
(4.6 to 5.4)
0.95 
(0.84 to 1.06)
Not reported
Target patients: 
adenocarcinoma or large-
cell carcinoma (n = 1000)
5.3 
(4.8 to 5.7)
4.7 
(4.4 to 5.4)
0.90 
(0.79 to 1.02)
Not reported
Patients with 
adenocarcinoma (n = 847)
5.5 
(4.9 to 5.7)
5.0 
(4.5 to 5.5)
0.90 
(0.78 to 1.03)
Not reported
Patients with large-cell 
carcinoma (n = 153)
4.4 
(3.0 to 5.8)
4.2 
(3.5 to 4.7)
0.89 
(0.65 to 1.24)
Not reported
Patients with NSCLC-NOS 
(n = 252)
4.5 
(4.0 to 5.5)
5.6 
(4.7 to 5.9)
1.28 
(0.99 to 1.67)
Not reported
Tumour response rate
All randomised patients 
including squamous NSCLC 
(n = 1725)
27.15 24.68 Not 
applicable
Not reported
Patients with non-squamous 
histology (n = 1252)
28.64 22.24 Not 
applicable
Not reported
Target patients: 
adenocarcinoma or large-
cell carcinoma (n = 1000)
Not reported Not reported Not 
applicable
Not reported
Patients with 
adenocarcinoma (n = 847)
28.90 21.65 Not 
applicable
Not reported
Patients with large-cell 
carcinoma (n = 153)
27.63 27.27 Not 
applicable
Not reported
Patients with NSCLC-NOS 
(n = 252)
Not reported Not reported Not 
applicable
Not reported
CI, confidence interval; HR, hazard ratio; NSCLC-NOS, non-small cell lung cancer-not otherwise specified.
a Non-inferiority.
b Superiority.
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from a de novo economic model developed by the 
manufacturer.
A Markov model was developed to evaluate 
the cost-effectiveness of pemetrexed/cisplatin 
compared with gemcitabine/cisplatin, docetaxel/
cisplatin and gemcitabine/carboplatin. The 
clinical data used in the economic evaluation were 
primarily generated from the JMDB trial,5 with 
additional data from the two further trials used in 
the indirect comparisons analysis.8,9 Although the 
economic evaluation was trial-based, the modelling 
component enabled the extrapolation of health 
effects beyond the period of 30 months of the 
trial, adopting a lifetime horizon (taken as 6 years) 
for the consideration of costs and benefits. The 
perspective of the model was that of the UK NHS 
and Personal Social Services.
The ERG identified a series of problems with 
this economic model. As a result, three different 
versions of the model were submitted to NICE and 
considered by the ERG. The ICERs estimated by 
this final version of the model ranged from £8056 
to £33,065, depending on the comparator, the 
population and the application of a continuation 
rule.
Commentary on the robustness 
of submitted evidence
The JMDB trial was a randomised controlled 
head-to-head clinical trial that was well-designed, 
used robust randomisation techniques and was 
suitably powered to demonstrate the primary 
non-inferiority objective of the trial for the 
total population of patients with squamous and 
non-squamous NSCLC. Subgroup analyses of 
patients with non-squamous NSCLC and the 
manufacturer’s own defined target population were 
conducted. The subgroups appeared to be clinically 
appropriate and confidence in the robustness of 
the findings was increased by the fact that these two 
subgroups were both pre-specified and relatively 
large in size.
Evidence from the indirect comparisons should 
be treated with caution as other comparators 
defined in the original scope and decision problem 
(vinorelbine and paclitaxel in combination 
with cisplatin or carboplatin and docetaxel/
carboplatin) were excluded from the indirect 
comparisons analysis. In addition, the statistical 
approach employed to generate the findings 
is not considered to be the most optimal, as 
calculations were based on median survival times 
and individual trial arm level data from within 
trials were compared, thus ignoring the benefits 
of randomisation. Finally, data was only available 
for all patients with NSCLC (i.e. squamous or non-
squamous NSCLC) in all but the JMDB trial. Thus, 
the HRs for each subgroup in the JMDB trial were 
used to estimate HRs for subgroups of patients 
given gemcitabine/carboplatin or docetaxel/
cisplatin in the comparator trials. However, it was 
impossible to confirm from the data reported by 
the published papers of these trials whether the 
relative effects found in the JMDB trial would be 
consistent across subgroups for these patients.
Examination of the final version of the economic 
model submitted to NICE and considered by the 
ERG showed that, although minor modifications 
had been made to correct some of the problems 
identified by the ERG with earlier versions, the 
model still failed to adequately address the crucial 
problems at the heart of the model. These were 
beyond the remit of the ERG to address, and 
included:
• The chosen model design was not obviously 
suitable for modelling the disease and 
treatments described in the published clinical 
trial, imposing as it does serious constraints 
TABLE 2 Summary of the unadjusted trial results for all patients with squamous or non-squamous non-small cell lung cancer
Study Treatment arm
Median (range) 
OS (months)
Median (range) 
PFS (months)
Median 
response rate 
JMDB trial Pemetrexed/cisplatin (n = 862) 10.3 (9.8 to 11.2) 4.8 (4.6 to 5.3) 27%
(ITT population)5 Gemcitabine/cisplatin (n = 863) 10.3 (9.6 to 10.9) 5.1 (4.6 to 5.5) 25%
Zatloukal 20038 Gemcitabine/cisplatin (n = 87) 8.8 (6.7 to 10.5) 5.9 (4.3 to 6.7) 41%
Gemcitabine/carboplatin (n = 89) 8.0 (6.9 to 11.4) 4.8 (4.0 to 5.6) 29%
Schiller 20029 Gemcitabine/cisplatin (n = 301) 8.1 (7.2 to 9.4) 4.2 (3.7 to 4.8) 22%
Docetaxel/cisplatin (n = 304) 7.4 (6.6 to 8.8) 3.7 (2.9 to 4.2) 17%
ITT, intention to treat; OS, overall survival; PFS, progression-free survival
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on the possibility of representing the observed 
patterns of response to treatment and 
progression of disease.
• The implementation of the model was marked 
by examples of basic errors with marked 
consequences.
• There is little evidence of a systematic 
approach by the manufacturer to identifying 
and eliminating errors in the development of 
the model, or of attempting to replicate the 
prime source of information for the model, i.e. 
the JMDB trial itself.
• The restriction of comparators to those that are 
relatively high cost is likely to give a misleading 
impression of the true cost-effectiveness 
of pemetrexed regimen. Furthermore, 
gemcitabine will be off patent in the UK from 
March 2009 and may soon become available 
in generic form at a lower price. This was not 
considered in the manufacturer’s model.
• The methods used for adjusting treatment 
effects (positive and negative) when a scenario 
is used with fewer treatment cycles than in the 
trial evidence are not obviously robust and 
defensible and may tend to overestimate the 
outcome benefits to be expected from use of 
pemetrexed/cisplatin, while underestimating 
the additional cost.
Thus, the ERG believed that the model requires 
extensive modification and redesign, subjected to 
thorough validation against the JMDB trial results. 
A full quality audit was also required as it is likely 
that further model inconsistencies may be present 
that have not yet been identified.
Conclusions
Given that the JMDB trial subgroup analyses were 
predefined and a large number of patients were 
included, confidence in the robustness of the 
subgroup results was increased. These findings 
provide important evidence warranting further 
exploration that pemetrexed/cisplatin may be 
superior to gemcitabine/cisplatin in terms of 
prolonging overall survival in patients with non-
squamous NSCLC, particularly in those with 
adenocarcinoma or large-cell carcinoma.
Identifying patients in the manufacturer’s target 
population requires more specific histological 
testing than is standard across all UK centres 
at present. In the JMDB trial, patients with 
adenocarcinoma represented half of all 
patients. The known proportion of patients with 
adenocarcinoma in the UK is not presented in 
the manufacturer’s submission which reports only 
recent audit data suggesting a quarter of patients 
with NSCLC have adenocarcinoma.4 Thus, the 
accurate diagnosis for this significant group of 
patients may be a particular challenge.
As no other regimens recommended by NICE 
were compared in head-to-head clinical trials with 
pemetrexed/cisplatin, the manufacturer undertook 
an indirect comparisons’ analysis. This suggested 
pemetrexed/cisplatin to be the most efficacious 
regimen when also compared with gemcitabine/
carboplatin, the most common regimen in the UK, 
or docetaxel/cisplatin. However, because not all 
relevant comparators were included in the indirect 
comparisons’ analysis and because of the statistical 
method employed to undertake this analysis, these 
findings should be treated with caution.
The ERG found a number of substantial problems 
with the economic model. Most seriously, there 
were underlying structural problems and logic 
errors which had still not been addressed in 
the third version of the model submitted by the 
manufacturer. Consequently, the model was unable 
to replicate the response rates arising in the JMDB 
trial and it was impossible to provide reliable 
ICERs. Thus, even in its modified form, the 
economic model was not able to provide estimates 
upon which to base a decision regarding the cost-
effectiveness of pemetrexed/cisplatin.
Summary of NICE guidance 
issued as a result of the STA
Given the above conclusions, NICE guidance was 
only issued after considering additional evidence 
subsequently submitted by the manufacturer (two 
models and an ‘in-trial’ analysis) and a critique 
of this evidence by the ERG. The very short time 
available to the ERG to consider the new evidence 
precluded a comprehensive assessment. The ERG 
believed that some issues of face validity had not 
been appropriately addressed and thus the ERG 
presented a simple exploratory analysis combining 
its own survival projections with key cost estimates 
obtained from individual patient data provided by 
the manufacturer from the JMDB trial. Compared 
to gemcitabine, this resulted in ICERs ranging 
from £17,162 to £30,142 per QALY, depending 
on the patient population, the maximum number 
of cycles of chemotherapy and whether a cycle 
based efficacy adjustment was applied or not. 
Thus the guidance issued by NICE in September 
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2009 states that pemetrexed in combination with 
cisplatin is recommended as an option for the first-
line treatment of patients with locally advanced 
or metastatic NSCLC only if the histology of the 
tumour has been confirmed as adenocarcinoma 
or large-cell carcinoma. People who are currently 
being treated with pemetrexed for NSCLC but who 
do not meet this criterion should have the option 
to continue their therapy until they and their 
clinicians consider it appropriate to stop.
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of the authors and do not necessarily reflect those of 
the Department of Health.
Discussion of ERG reports is invited. Visit the HTA 
website correspondence forum (www.hta.ac.uk/
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of topotecan 
in combination with cisplatin for the treatment 
of recurrent and stage IVB carcinoma of the 
cervix, in accordance with the licensed indication, 
based upon the evidence submission from the 
manufacturer to the National Institute for 
Health and Clinical Excellence (NICE) as part 
of the single technology appraisal (STA) process. 
The outcomes measured were overall survival, 
progression-free survival, response rates, adverse 
effects of treatment, health-related quality of life 
(HRQoL) and quality-adjusted life-years (QALYs) 
gained. The manufacturer stated that topotecan 
plus cisplatin is the only combination regimen 
to date to have demonstrated a statistically 
significant survival advantage compared to cisplatin 
monotherapy in the licensed population. The 
clinical evidence came from three clinical trials 
comparing topotecan plus cisplatin with cisplatin 
monotherapy (GOG-0179), topotecan plus cisplatin 
with paclitaxel plus cisplatin (GOG-0169), and four 
cisplatin-based combination therapies: topotecan 
plus cisplatin, paclitaxel plus cisplatin, gemcitabine 
plus cisplatin, and vinorelbine plus cisplatin 
(GOG-0204). Results from GOG-0179 showed 
greater median overall survival with topotecan 
plus cisplatin than with cisplatin monotherapy: 
9.4 months versus 6.5 months. Similar results were 
also reported for median progression-free survival. 
Response rates also showed an advantage with 
topotecan plus cisplatin compared with cisplatin 
monotherapy. The response rates in patients 
receiving cisplatin monotherapy were very low, but 
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the potential reasons for this were not discussed 
in the manufacturer’s submission. Patients 
receiving topotecan plus cisplatin experienced a 
greater number of adverse events and the ERG 
was concerned with some of the assumptions 
related to HRQoL. In the base-case direct 
comparison, the incremental cost-effectiveness 
ratio (ICER) of topotecan plus cisplatin versus 
cisplatin monotherapy was £17,974 per QALY 
in the main licensed population, £10,928 per 
QALY in the cisplatin-naive population (including 
stage IVB patients) and £32,463 per QALY in 
sustained cisplatin-free interval patients. In 
response to the point for clarification raised by 
the ERG, the manufacturer submitted a revised 
indirect comparison incorporating HRQoL and 
a longer time horizon. Where the hazard ratio 
derived from GOG-0169 was employed, paclitaxel 
plus cisplatin was dominated by topotecan plus 
cisplatin, but, where the hazard ratio from GOG-
0204 was adopted, paclitaxel plus cisplatin was 
found to have an ICER of £13,260 per QALY 
versus topotecan plus cisplatin. At present there 
is a paucity of evidence available on the clinical 
effects of topotecan plus cisplatin and the effects 
of palliative treatment in general for women with 
advanced and recurrent carcinoma of the cervix. 
Further trials, or the implementation of registries, 
are required to establish the efficacy and safety of 
topotecan plus cisplatin. The guidance issued by 
NICE on 28 October 2009 as a result of the STA 
states that topotecan in combination with cisplatin 
is recommended as a treatment option for women 
with recurrent or stage IVB cervical cancer, only 
if they have not previously received cisplatin. 
Women who have previously received cisplatin 
and are currently being treated with topotecan in 
combination with cisplatin for the treatment of 
cervical cancer should have the option to continue 
therapy until they and their clinicians consider it 
appropriate to stop.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, where most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG); an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
entitled ‘Topotecan for the treatment of recurrent 
and stage IVB carcinoma of the cervix’.2
Description of the underlying 
health problem
Cervical cancer is the second most common 
malignant neoplastic disease among women 
worldwide, with a standardised incidence rate of 
8.4 per 100,000 females in the UK.
Most patients in the UK are diagnosed with early 
disease and surgery may be curative. In more 
advanced non-metastatic disease, radiotherapy may 
be administered as a potentially curative treatment. 
For recurrent or metastatic disease, treatment 
is, in most cases, palliative. Stage IVB cervical 
cancer is the most advanced form of the disease, 
in which the cancer has spread to more distant 
organs.3 The median survival for stage IVB cervical 
cancer is very low, at approximately 9–10 months, 
with 30% survival at 1 year and 2–5% survival at 
2 years (Paul Symonds, personal communication to 
GlaxoSmithKline UK, 2009).
Cisplatin has long been considered the most 
effective platinum-based chemotherapy for the 
treatment of recurrent or advanced cervical 
cancer,4–8 either alone or in combination with other 
chemotherapies. Although the use of combination 
therapies, particularly paclitaxel in combination 
with either cisplatin or carboplatin or topotecan 
in combination with cisplatin, has increased, 
only topotecan in combination with cisplatin 
has been explicitly licensed for this indication; 
recommended for restricted use within NHS 
Scotland and NHS Wales for the treatment of 
cisplatin-naive patients only.
Scope of the evidence 
review group report
The ERG report appraised the clinical effectiveness 
and cost-effectiveness of topotecan in combination 
with cisplatin (within its licensed indications – 
see Figure 1) for the treatment of recurrent and 
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stage IVB carcinoma of the cervix. The outcomes 
measured were overall survival, progression-
free survival, response rates, adverse effects of 
treatment, health-related quality of life (HRQoL) 
and quality-adjusted life-years (QALYs). The 
manufacturer stated that topotecan plus cisplatin 
is the only combination regimen to date to have 
demonstrated a statistically significant survival 
advantage compared to cisplatin monotherapy in 
the licensed population.
The manufacturer recommended that topotecan 
is administered in combination with cisplatin; 
0.75 mg/m2 per day of topotecan, administered as 
30-minute intravenous infusion on days 1, 2 and 
3, with one dose of 50 mg/m2 per day of cisplatin 
administered on day 1 following topotecan. 
Treatment is repeated every 21 days for six cycles 
or until disease progression.
The manufacturer’s submission focused on direct 
evidence from a phase III randomised controlled 
clinical trial (GOG-0179) comparing topotecan 
plus cisplatin with cisplatin monotherapy, and 
indirect clinical evidence from a phase III trial 
(GOG-0169) comparing topotecan plus cisplatin 
with paclitaxel plus cisplatin. A second direct 
comparison trial (GOG-0204) was mentioned, 
which compared four cisplatin-based combination 
therapies: topotecan plus cisplatin, paclitaxel 
plus cisplatin, gemcitabine plus cisplatin, and 
vinorelbine plus cisplatin. GOG-0179 included 
patients outside the licensed population, and the 
manufacturer undertook subgroup analyses to 
reflect the different subgroups within the licensed 
population, namely: licensed population including 
or excluding stage IVB patients, cisplatin-naive 
patients, and patients with sustained cisplatin-free 
interval (SCFI) longer than 180 days.
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FIGURE 1 Schematic of study population and subgroups analysed in the manufacturer’s submission 1. Licensed population, consisting of: 
1a. licensed population excluding IVB patients; 1b. stage IVB patients (by definition cisplatin-naive, as they are newly presenting). 2. Cisplatin-
naive population, consisting of: 2a. cisplatin-naive recurrent population excluding stage IVB patients; b. stage IVB patients. 3. Patients with a 
sustained cisplatin-free interval (SCFI; prior cisplatin > 180 days). 4. A further subgroup was analysed specifically for an indirect comparison 
of topotecan plus cisplatin versus paclitaxel plus cisplatin. The cisplatin-naive (for indirect analysis) population contains all cisplatin-naive 
patients in GOG-0179 for comparison with patients in a second study (GOG-0169).
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The manufacturer submitted two separate cost-
effectiveness comparisons: a trial-based direct 
comparison between topotecan plus cisplatin and 
cisplatin monotherapy based on patient-level data 
from GOG-0179 and evaluated using the statistical 
package sas®, considered by the manufacturer to be 
the primary analysis within their submission; and a 
Microsoft excel model-based indirect comparison 
between topotecan plus cisplatin and paclitaxel 
plus cisplatin, considered to be a secondary 
analysis.
Methods
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s submission to NICE as part of the 
STA process.
The ERG replicated the manufacturer’s amended 
search strategy, and attempted to reproduce its 
patient-level analysis. The ERG was unable to 
comprehensively validate the patient-level analysis 
because of the manufacturer’s failure to provide 
a fully executable sas®-based model, and instead 
focused on the excel-based analysis. The ERG 
made a number of revisions to the manufacturer’s 
model, including altering the assumptions 
related to utility values, the costs of administering 
treatment, and the number of vials of topotecan 
utilised.
Results
Summary of submitted 
clinical evidence
The GOG-0179 trial reported greater median 
overall survival with topotecan plus cisplatin than 
with cisplatin monotherapy: 9.4 months versus 
6.5 months. The unadjusted hazard ratio (HR) of 
0.76 [95% confidence interval (CI) 0.59 to 0.98, 
p = 0.033] translates into a 24% reduction in 
mortality with combination therapy. Similar results 
were also reported for median progression-free 
survival in GOG-0179: 4.6 months (topotecan plus 
cisplatin) versus 2.9 months (cisplatin), HR 0.76 
(95% CI 0.60 to 0.97, p = 0.027).
Response rates also showed an advantage with 
topotecan plus cisplatin (24%) compared with 
cisplatin monotherapy (12%) (p = 0.0073). The 
response rates in patients receiving cisplatin 
monotherapy were very low, but the potential 
reasons for this were not discussed in the 
manufacturer’s submission.
The safety profile of topotecan plus cisplatin was 
reported to be predictable and manageable, and 
there was reportedly no evidence to suggest that 
HRQoL was significantly reduced in patients 
receiving combination therapy. However, patients 
receiving topotecan plus cisplatin experienced a 
greater number of adverse events and the ERG is 
concerned with some of the assumptions related to 
HRQoL.
Subgroup analyses were undertaken and showed 
favourable results towards topotecan plus cisplatin 
(Table 1), but the results should be interpreted with 
caution as the number of patients in quite a few of 
the subgroups was small and some of the analyses 
were performed post hoc.
For overall survival, the indirect comparison 
between GOG-0179 and GOG-0169 showed non-
significant results in favour of topotecan plus 
cisplatin compared with paclitaxel plus cisplatin: 
HR 0.72 (95% CI 0.46 to 1.15).
The GOG-0204 trial was closed early as all 
experimental arms were unlikely to demonstrate a 
significant advantage compared with paclitaxel plus 
cisplatin. In response to a point for clarification 
raised by the ERG, the manufacturer conducted 
direct and indirect comparisons including data 
from GOG-0204. The direct comparison favoured 
paclitaxel plus cisplatin (HR 1.27, 95% CI 0.96 
to 1.69), while the pooled data using direct and 
indirect evidence from GOG-0169, GOG-0179 and 
GOG-0204 favoured topotecan plus cisplatin (HR 
0.98, 95% CI 0.73 to 1.23), but neither result was 
statistically significant.
Summary of submitted cost-
effectiveness evidence
In the base-case direct comparison, the incremental 
cost-effectiveness ratio (ICER) of topotecan plus 
cisplatin versus cisplatin monotherapy was £17,974 
per QALY in the main licensed population, 
£10,928 per QALY in the cisplatin-naive 
population (including stage IVB patients) and 
£32,463 per QALY in SCFI patients.
Results for the indirect comparison were presented 
only for a cisplatin-naive population, and outcomes 
were expressed in terms of life-years gained only. 
In the base-case indirect comparison, paclitaxel 
plus cisplatin was dominated by topotecan plus 
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cisplatin, which in turn had a cost per life-year 
gained of £19,964 versus cisplatin monotherapy; 
where the HR used to calculate overall survival 
with paclitaxel plus cisplatin was taken from GOG-
0204 (rather than derived from GOG-0169, as in 
the base case), paclitaxel plus cisplatin was found 
to have a cost per life-year gained of £982 versus 
topotecan plus cisplatin.
In response to the point for clarification raised by 
the ERG, the manufacturer submitted a revised 
indirect comparison incorporating HRQoL and 
a longer time horizon. Similar to the previous 
analysis, where the HR derived from GOG-
0169 was employed, paclitaxel plus cisplatin was 
dominated by topotecan plus cisplatin, but, where 
the HR from GOG-0204 was adopted, paclitaxel 
plus cisplatin was found to have an ICER of 
£13,260 per QALY versus topotecan plus cisplatin.
The ERG made a number of revisions to this 
model to explore alternative assumptions to those 
employed by the manufacturer. Where the number 
of vials used was assumed to be minimised (or 
maximised) because of alternative assumptions 
about possible wastage, the ERG found topotecan 
plus cisplatin to have an ICER versus cisplatin 
monotherapy of £26,778 (£34,327) per QALY in 
the cisplatin-naive patient population and £58,872 
(£73,833) per QALY in the full licensed population 
from GOG-0179. These ICERs were considered to 
be potentially conservative as no account was taken 
of the potential impact of dose reductions because 
of adverse events on the acquisition costs of the 
interventions. In order to consider the potential 
impact of dose reduction, the ERG employed 
a ‘hybrid’ approach combining estimates from 
the manufacturer’s patient level and the ERG’s 
revised model analyses. Where wastage of vials was 
assumed to be minimised, the ICER of topotecan 
plus cisplatin versus cisplatin monotherapy fell 
to £19,815 in the cisplatin-naive population 
and £53,868 in the licensed population. While 
assuming maximum wastage of topotecan, the 
ICER of topotecan plus cisplatin versus cisplatin 
monotherapy rose to £27,362 in the cisplatin-naive 
population and £68,826 in the licensed population.
Topotecan plus cisplatin, paclitaxel plus cisplatin, 
and cisplatin monotherapy were compared in a 
fully incremental analysis; topotecan plus cisplatin 
was found to extendedly dominate paclitaxel plus 
cisplatin in most scenarios where the GOG-0169 
HR was adopted, but was dominated by paclitaxel 
plus cisplatin in all scenarios where the GOG-0204 
HR was adopted.
Commentary on the robustness 
of submitted evidence
The main strength of the direct comparison was the 
potential for the results to have a very high internal 
validity due to the use of patient-level data from 
a recent, relevant and seemingly well-conducted 
trial (GOG-0179). This was considered to be a 
potential strength only because the manufacturer 
did not provide in a timely manner the necessary 
code and data sets for the ERG to validate fully the 
programming of this comparison.
A further strength of the direct comparison was 
the presentation of results for the main licensed 
population and a series of subgroups within that, 
highlighting the population gaining most benefit 
from treatment, and allowing variability in the cost-
effectiveness estimates to be considered. However, 
the limitations of subgroup analyses should be 
borne in mind.
The main strengths of the indirect comparison 
were the relatively high degree of transparency 
within the submitted excel model and the high 
degree of consistency between the electronic model 
and the submitted report.
The lack of transparency regarding the literature 
search and rationale for exclusion of potentially 
relevant trials was a limitation, and this was not 
satisfactorily addressed in the manufacturer’s 
response document.
For the direct comparison, the results from GOG-
0204 were not formally included in the submission. 
For the indirect comparison, it was not clear 
that a comprehensive network of evidence was 
investigated. Potentially relevant studies were 
excluded by the manufacturer on the basis that 
the comparators were not licensed for use in this 
population; however, the comparator selected 
for the indirect comparison (i.e. paclitaxel plus 
cisplatin) was not licensed – this contradiction was 
not satisfactorily explained.
The analyses submitted for the cost-effectiveness 
evidence were incomplete and required 
considerable clarification. The lack of transparency 
regarding the programming of the direct 
comparison was a significant weakness; the coding 
was incompletely submitted in a non-executable 
form and with evidence of errors. There were also 
concerns surrounding the methods used, which 
may potentially overestimate the incremental 
QALY gains associated with topotecan plus 
cisplatin. The primary analysis based on GOG-
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0179 suffers from a lack of external validity as it 
makes no comparison between topotecan plus 
cisplatin and other relevant treatment comparators 
other than cisplatin monotherapy.
The indirect comparison initially submitted 
neglected to consider HRQoL, reporting life-
years gained instead of QALYs, although this was 
rectified following a request from the ERG. The 
results were only presented for a single population 
(cisplatin-naive patients, including patients 
with persistent disease) and the model was not 
probabilistic, so that uncertainty surrounding the 
cost-effectiveness results could not be appropriately 
quantified.
Both comparisons also failed to properly justify a 
number of assumptions over costs, including the 
cost of administering treatments, the number of 
vials of topotecan needed per cycle and the costs 
of adverse events, all of these were considered for 
revision by the ERG.
Conclusions
At present there is a paucity of evidence available 
on the clinical effects of topotecan plus cisplatin 
and the effects of palliative treatment in general 
(including various off-license drugs regularly used 
in UK clinical practice) for women with advanced 
and recurrent carcinoma of the cervix.
Further trials, or the implementation of registries, 
are required to establish the efficacy and safety 
of topotecan plus cisplatin. Such research should 
assess all aspects of quality of life, including the 
impact of treatment toxicities, scheduling and 
convenience to the patient. It is also important 
to untangle further which patients will benefit 
the most from treatments and the factors that 
potentially moderate these benefits. Further 
research to provide appropriate utility values for 
patients with cervical cancer, reflecting both the 
stage and course of disease (e.g. impact of disease 
progression) as well as the specific impact of 
individual therapies, would be beneficial.
Key issues
For the direct comparison submitted by the 
manufacturer, there was a paucity of clinical 
effectiveness evidence available, and the 
manufacturer made limited use of the results from 
GOG-0204. The ERG questioned the handling 
and reporting of quality of life data and whether 
the results were representative of the whole patient 
experience. For the economic evaluation, key issues 
relate to the appropriateness of the mapped utility 
values adopted, the reasonableness of the costing 
assumptions, the external validity of an analysis 
with only a single comparator, and (perhaps most 
importantly) the validity and transparency of the 
sas analysis.
In terms of the indirect comparison, a potentially 
relevant network of indirect evidence has not been 
fully explored, although the ERG acknowledges 
that the quality of such evidence would be limited. 
The inclusion of direct evidence from GOG-0204 
(further results will shortly be available) and 
evidence from a forthcoming Cochrane Review 
would increase the network of evidence and enable 
further assessment of the clinical effectiveness and 
cost-effectiveness of treatments used in current UK 
practice.
Key issues in relation to the indirect comparison 
were the appropriateness of the utility values, the 
reasonableness of the costing assumptions, and 
the appropriate source of the HR used to estimate 
survival for paclitaxel plus cisplatin – deriving 
this HR from GOG-0169 favours topotecan plus 
cisplatin, while deriving it from GOG-0204 favours 
paclitaxel plus cisplatin.
Areas of uncertainty
There is uncertainty surrounding the population(s) 
that will benefit most from treatment with 
topotecan plus cisplatin. The number of patients 
who have received chemoradiation is likely 
to increase in the future, thus the number of 
cisplatin-naive patients will diminish. This raises 
the question of the applicability of the results to 
current and future clinical practice.
The economic submissions are subject to significant 
uncertainty over the utility values and cost 
assumptions adopted by the manufacturer, and this 
uncertainty feeds into the results of the subsequent 
analyses.
Summary of NICE guidance 
issued as a result of the STA
At the time of writing, the final appraisal 
consultation document issued by NICE on 28 
October 2009 states that:
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Topotecan in combination with cisplatin, is 
recommended as a treatment option for women 
with recurrent or stage IVB cervical cancer only if 
they have not previously received cisplatin.
Women who have previously received cisplatin 
and are currently being treated with topotecan in 
combination with cisplatin for the treatment of 
cervical cancer should have the option to continue 
therapy until they and their clinicians consider it 
appropriate to stop.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of trabectedin 
for the treatment of advanced metastatic soft 
tissue sarcoma, in accordance with the licensed 
indication, based on the evidence submission 
from the manufacturer to NICE as part of the 
single technology appraisal (STA) process. The 
outcomes stated in the manufacturer’s definition 
of the decision problem were overall survival 
(OS), progression-free survival (PFS), response 
rates, adverse effects of treatment, health-related 
quality of life, and cost per quality-adjusted life-
year (QALY) gained. The clinical evidence was 
derived from one randomised controlled trial 
(RCT), in which the licensed dose of trabectedin 
was compared with a different dose of trabectedin, 
and three phase II studies. In the RCT, the median 
OS was 13.9 months for the licensed dose of 
trabectedin, which was not significantly different 
from that for the comparator dose of trabectedin, 
which was 11.8 months. From the phase II 
uncontrolled trials, median OS was reported as 9.2 
or 12.8 months. The RCT reported significantly 
superior PFS for the licensed dose of trabectedin 
(median 3.3 months) over the comparator 
trabectedin dose (median 2.3 months). One phase 
II uncontrolled trial reported median PFS as 1.9 
months in the licensed dose of trabectedin. The 
RCT reported PFS rates at 6 months were 35.5% 
for the licensed dose of trabectedin, and 27.5% 
for the comparator dose of trabectedin. From the 
phase II uncontrolled trials, PFS rates at 6 months 
were 24.4% or 29%. For the RCT, deaths attributed 
to trabectedin occurred in 3.1% of the licensed 
dose, and 2.3% of the comparator group. The most 
common severe adverse events were neutropenia, 
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although with a low rate of febrile neutropenia, 
thrombocytopenia, and aspartate aminotransferase 
and alanine aminotransferase elevation, although 
these were reported to be non-cumulative and 
reversible. Following dialogue iterations with 
the ERG team, the manufacturer revised the 
model twice. However, despite revisions, errors/
inconsistencies were found in the latest version of 
the model and were corrected by the ERG (only 
for the base case). In the latest manufacturer’s 
submission, the cost per QALY gained of 
trabectedin compared with best supportive care 
(BSC) was estimated to be £56,985 for the base 
case using effectiveness from the STS (Soft Tissue 
Sarcomas)-201 trial for trabectedin and a pool 
analysis of the European Organisation for Research 
and Treatment of Cancer data set for BSC. This 
analysis was constrained to patients with L–
sarcomas only. When the joint uncertainty between 
parameters was considered, the cost-effectiveness 
acceptability curve showed that trabectedin has 
a very low probability of being cost-effective at a 
threshold of £30,000 per QALY gained compared 
with BSC for any scenario. The guidance has yet to 
be issued by NICE.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, where most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report for the STA 
entitled ‘Trabectedin for the treatment of advanced 
metastatic soft tissue sarcoma: a single technology 
appraisal’.2
Description of the underlying 
health problem
Trabectedin is licensed for patients with advanced 
metastatic soft tissue sarcoma having failed 
anthracycline and ifosfamide or for whom these 
agents are unsuitable.
Soft tissue sarcomas (STS) constitute a 
heterogeneous group of malignancies arising 
in soft tissues of the body including muscle, fat 
and blood vessels. The most frequent types are 
leiomyosarcoma and liposarcoma, which account 
for approximately 40–50% of all STS. There is 
an estimated annual incidence of 2000 STS in 
England and Wales (including gastrointestinal 
stromal tumour, which is excluded from this 
report).3 Approximately 50% of patients present 
with, or develop, advanced or metastatic disease.
Scope of the evidence 
review group report
The principal research question was to appraise 
the clinical effectiveness and cost-effectiveness 
of trabectedin within its licensed indication 
for the treatment of advanced metastatic soft 
tissue sarcoma. Trabectedin is licensed for use in 
patients with advanced metastatic STS who have 
failed anthracycline and ifosfamide, either in 
combination as first-line therapy or in sequence 
as first- and second-line therapy. No other 
chemotherapies are currently licensed in the UK 
for STS at this point in therapy. The comparator 
was best supportive care. Relevant outcomes were 
overall survival (OS), progression-free survival 
(PFS), response rates (including stabilisation), 
adverse effects of treatment, health-related quality 
of life, and cost per quality-adjusted life-year 
(QALY) gained.
The manufacturer submitted a state transition 
model developed in excel, with individuals 
followed up to 5 years (until death). The base 
case in the manufacturer’s submission assumed 
that patients treated with trabectedin enter the 
model in the progression-free state (PFS) while 
patients in the best supportive care (BSC) arm 
enter the model in the progressive disease (PD) 
state. The base case was limited to patients with 
leukaemia (L)-sarcomas. Additional analyses 
requested by the ERG adjust the base case to 
account for differences in the starting health state. 
In addition, the manufacturer presented three 
additional scenarios. The first scenario used the 
pooled effectiveness of trabectedin from three 
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uncontrolled phase II studies which was not limited 
to patients with L-sarcomas. In the second and 
third scenarios, the manufacturer assumed that a 
proportion of patients in BSC would receive further 
chemotherapies (either 33% or 100% of patients).
Methods
The ERG report comprised a critical review of 
the evidence for the clinical evidence and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process.
The ERG repeated, although could not 
replicate exactly, the searches undertaken by the 
manufacturer. The ERG does not believe that any 
relevant clinical or cost-effectiveness studies have 
been missed.
Following dialogue iterations with the ERG 
team, the manufacturer revised the model twice. 
However, despite revisions, errors/inconsistencies 
were found in the latest version of the model and 
were corrected by the ERG (only for the base 
case). These errors were identified by a review 
of the model structure and internal logic and 
the responsiveness of the results to changes in 
parameters values.
Results
Summary of submitted 
clinical evidence
Owing to the lack of any comparative trials 
comparing trabectedin and BSC, the main 
evidence in the manufacturer’s submission was 
derived from one phase II randomised trial, 
in which the licensed dose of trabectedin was 
compared with a different dose of trabectedin. In 
the randomised controlled trial (RCT), median 
OS was 13.9 months [95% confidence interval (CI) 
12.5 to 18.6] for the licensed dose of trabectedin 
(24-hour regimen every 3 weeks), which was 
not significantly different (p = 0.1985) from that 
for the comparator dose of trabectedin (weekly 
3-hour regimen) which was 11.8 months (95% 
CI 9.9 to 14.9). From the phase II uncontrolled 
trials, median OS was reported as 9.24 or 12.8 
months.5 Historical control data, presented by 
the manufacturer’s submission as equivalent to 
BSC, had median OS of 5.9–6.6 months.6 The 
RCT reported significantly (p = 0.04) superior PFS 
for the licensed dose of trabectedin (median 3.3 
months) over the comparator trabectedin dose 
(median 2.3 months). One phase II uncontrolled 
trial reported median PFS as 1.9 months in the 
licensed dose of trabectedin.5 The RCT reported 
PFS rates at 6 months were 35.5% (95% CI 27.1 
to 43.9) for the licensed dose of trabectedin, 
and 27.5% (95% CI 19.4 to 35.5) for the 
comparator dose of trabectedin. From the phase 
II uncontrolled trials, PFS rates at 6 months were 
24.4%7 or 29%.4 Historical control data, presented 
by the manufacturer’s submission as equivalent to 
BSC, reported PFS rates at 6 months of 14% for 
patients treated with ifosfamide or dacarbazine 
after failure of anthracycline or 8% for patients 
from pooled studies on ‘inactive’ regimens.
For the RCT, deaths attributed to trabectedin 
occurred in 3.1% of the licensed dose, and 2.3% of 
the comparator group. Safety data for the licensed 
dose of trabectedin from the included RCT and 
three phase II studies’ reported rates of grade 
3/4 haematological events varied: neutropenia 
34–61%; febrile neutropenia 0.8–7.0%; 
thrombocytopenia 12–19%; and anaemia 8–22%. 
Across the four included studies, rates of grade 
3/4 non-haematological events varied: aspartate 
aminotransferase (AST) elevation 26–48%; alanine 
aminotransferase (ALT) elevation 20–57%; nausea 
4–7%; vomiting 2–9%; and asthenia/fatigue 0–15%.
Summary of submitted cost-
effectiveness evidence
In the latest manufacturer’s submission, the cost 
per QALY gained of trabectedin compared with 
BSC was estimated to be £56,985 for the base 
case using effectiveness from the STS-201 trial for 
trabectedin and a pool analysis of the European 
Organisation for Research and Treatment of 
Cancer data set for BSC. This analysis was 
constrained to patients with L-sarcomas only.
The ERG was concerned that patients in the 
trabectedin arm began in a different health 
state than those in the BSC arm, and that those 
on trabectedin were assumed to have a higher 
starting utility. An exploratory analysis by the 
manufacturers in amending this assumption 
raised the cost per QALY gained for trabectedin 
compared with BSC to £61,064.
In addition to the base case, the manufacturer 
presented three additional scenarios. The first 
used the pooled effectiveness of trabectedin from 
three uncontrolled phase II studies which was not 
limited to patients with L-sarcomas; this produced 
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a cost per QALY gained of £50,017. In the second 
and third scenarios, the manufacturer assumed 
that a proportion of patients in BSC would receive 
further chemotherapies (either 33% or 100% of 
patients). The cost per QALY gained for these 
two scenarios was estimated to be £62,044 and 
£80,279 respectively. None of these three scenarios 
amended the model to take into consideration the 
different starting utilities between the trabectedin 
and BSC arms.
When the joint uncertainty between parameters 
was considered, the cost-effectiveness acceptability 
curve showed that trabectedin has a very low 
probability of being cost-effective at a threshold of 
£30,000 per QALY gained compared with BSC for 
any scenario.
Commentary on the robustness 
of submitted evidence
Limited data were available. The main evidence 
in the manufacturer’s submission was derived 
from one phase II randomised trial, in which the 
licensed dose of trabectedin was compared with a 
different dose of trabectedin. The population in 
this trial was limited to L-sarcomas. Supplementary 
data were presented from three uncontrolled phase 
II trials of the licensed dose of trabectedin. Owing 
to the lack of a relevant comparator group in the 
included trabectedin trials, the manufacturer’s 
submission reported data from a database of other 
studies that are suggested to equate to BSC. The 
manufacturer acknowledged there were limitations 
with these controls, which, in addition to being 
historical comparisons, were from studies with 
populations comprising types of STS not restricted 
to L-sarcomas, and Eastern Cooperative Oncology 
Group (ECOG) performance status not confined 
to 0–1. This would bias against these controls for 
effectiveness data. There were some data available 
for ifosfamide studies restricted to a population 
similar to the trabectedin trials. Data presented in 
the clinical effectiveness section did not have OS 
calculated appropriately in all cases, and for OS 
and PFS data, further chemotherapy was given to 
some patients, thus making treatment not just BSC.
Iterations were needed to amend errors found by 
the ERG, which included errors in the treatment 
cost and additional analyses to explore the likely 
impact of the different starting health states. The 
ERG, however, still had concerns regarding the 
structure of the model and its ability to capture 
the cost-effectiveness of trabectedin for adults 
with advanced soft tissue sarcoma after failure of 
anthracyclines and ifosfamide. Firstly, the ERG had 
concerns about the potential non-comparability 
between patients included in studies to derive the 
effectiveness for trabectedin and BSC despite the 
adjustment of the Weibull curves for age, gender, 
histopathology and World Health Organization 
performance score. Secondly, the base case focuses 
on patients with L-sarcomas only and may not 
be generalisable to patients with other forms 
of STS. Thirdly, despite the attempt to adjust 
for the differences in the starting health state, 
uncertainties still exist on the likely impact of 
such model structure. Fourthly, while no utility 
values are available for patients with STS, there are 
uncertainties about the appropriateness of using 
utility values for patients with lung cancer as a 
proxy for STS. Fifthly, the probabilistic sensitivity 
analyses did not capture all the uncertainty within 
the decision, for example, the model assumed no 
correlation between time to disease progression 
and OS, nor correlation between the utility 
estimates for health states or the number of 1-mg 
and 0.25-mg vials used. Finally, the proportion 
of patients treated did not vary according to the 
proportion of patients in PFS. It is unclear how 
incorporating these correlations would change the 
mean cost per QALY, although it is likely that the 
range in the results generated from the PSA would 
increase.
Conclusions
Although the ERG does not believe relevant 
studies of trabectedin have been missed, the 
manufacturer’s submission contained only one 
phase II RCT comparing trabectedin at the 
licensed dose compared with trabectedin at a 
lower dose, with population L-sarcoma patients 
with ECOG performance status of 0–1. Further 
evidence was presented from phase II uncontrolled 
trials of trabectedin. Data for BSC were taken 
from historical controls from a database of other 
studies. The manufacturer acknowledges that 
there are limitations with these controls. There 
was a rate of deaths due to toxicity of 3.1% for the 
licensed dose of trabectedin in the RCT. The most 
common severe adverse events were neutropenia, 
although with a low rate of febrile neutropenia, 
thrombocytopenia, and AST and ALT elevation, 
although these were reported to be non-cumulative 
and reversible.
Despite iterations with the ERG, the ability of 
the model to capture the cost-effectiveness of 
trabectedin for adults with advanced STS after 
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failure of anthracyclines and ifosfamide is unclear. 
Uncertainties exist about the potential non-
comparability between patients in the trabectedin 
and BSC arm, the likely impact of the differences 
in the starting health state and the use of utility 
values for lung cancer as a proxy for STS patients. 
It is also unclear how results for the base case 
would be generalisable to patients with other 
forms of STS.
Summary of NICE guidance 
issued as a result of the STA
At the time of writing, the guidance issued by 
NICE in February 20108 states that:
Trabectedin is recommended as a treatment option 
for people with advanced soft tissue sarcoma if: 
treatment with anthracyclines and ifosfamide 
has failed, or they are intolerant of or have 
contraindications for treatment with anthracyclines 
and ifosfamide; and the acquisition cost of 
trabectedin for treatment needed after the fifth 
cycle is met by the manufacturer. This last clause 
reflects the patient access scheme submitted by the 
manufacturer, with the manufacturer offering the 
acquisition cost of the drug after the fifth cycle, this 
led to a considerable reduction of the ICER, from 
£61,000 to about £34,000.
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Abstract
This paper presents a summary of the evidence 
review group (ERG) report into the clinical 
effectiveness and cost-effectiveness of azacitidine 
(aza) compared with conventional care regimes 
(CCR) for higher risk patients with myelodysplastic 
syndrome (MDS), chronic myelomonocytic 
leukaemia (CMML) and acute myeloid leukaemia 
(AML), based on the evidence submission from 
the manufacturer to the National Institute for 
Health and Clinical Excellence (NICE) as part 
of the single technology appraisal process. The 
patient outcomes governing relative effectiveness 
and cost-effectiveness were defined as overall 
survival, time to progression (TTP) to AML, 
adverse events and health-related quality of life 
(HRQoL). The clinical evidence was derived from 
an open-label randomised controlled trial referred 
to as study AZA-001. It compared aza with CCR 
in 358 patients with higher risk MDS, CMML and 
AML 20–30% blasts. The outcomes reported in 
AZA-001 included overall survival, TTP to AML 
and adverse events. No HRQoL results were 
reported; however, outcomes likely to impact on 
HRQoL were provided. The results showed that: 
the median overall survival was 24.5 months on 
aza, compared with 15.0 months in the CCR group 
(p = 0.0001); the response rates were low (complete 
remission 17% aza versus 8% CCR); the median 
time to transformation to AML was greater in the 
aza group (17.8 versus 11.5 months; p < 0.0001); 
and of patients who were red blood cell (RBC) 
transfusion-dependent at baseline, 45% of those 
on aza became RBC transfusion-independent 
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during the treatment period, compared with 
11.8% in the CCR group (p < 0.0001). The ERG 
reran the submission’s search strategies after some 
modifications incorporating minor improvements. 
The ERG analysed the submitted economic 
model (model 1) and identified a number of 
inconsistencies and errors within the model. 
The manufacturer submitted a revised model for 
analysis by the ERG. Using the issues identified 
in the earlier analysis, the ERG conducted those 
repairs to the revised model that were feasible 
within time constraints. The ERG ran this version 
in probabilistic sensitivity analyses to generate 
cost-effectiveness acceptability frontiers. The 
results of these exploratory analyses indicated that: 
for standard-dose chemotherapy (SDC)-treated 
patients, of six treatment options available, best 
supportive care (BSC) was likely the most cost-
effective option up to a threshold of £51,000/
quality-adjusted life-year (QALY) [beyond £51,000/
QALY, aza + low-dose chemotherapy (LDC) became 
cost-effective]; for LDC-treated patients, of four 
options available, BSC was again the most cost-
effective option up to a willingness-to-pay threshold 
of £51,000/QALY (aza + LDC became cost-effective 
after £51,000/QALY); for BSC-treated patients, 
aza + BSC became cost-effective relative to BSC 
at a threshold of about £52,000/QALY. The ERG 
considers these results exploratory and considers 
that they should be viewed with caution. The 
AZA-001 study showed that, compared with CCR, 
those MDS patients receiving aza had prolonged 
median survival, had delayed progression to AML, 
had reduced dependence on transfusions and had 
a small improvement in response rate. Given the 
general paucity of economic modelling work in 
MDS and the limitations of the submitted industry 
model there is an evident need for an independent 
cost-effectiveness analysis of aza in MDS. At the 
time of writing, the guidance appraisal consultation 
document issued by NICE on 4 March 2010 states 
that azacitidine is not recommended as a treatment 
option for people not eligible for haemopoietic 
stem cell transplantation with the the following 
conditions: intermediate-2 and high-risk MDS 
according to the International Prognostic Scoring 
System, CMML with 10-29% marrow blasts without 
myeloproliferative disorder, or with AML with 20-
30% blasts and multilineage dysplasia, according to 
World Health Organization classification.
Introduction
The National Institute for Health and Clinical 
Excellence (NICE) is an independent organisation 
within the NHS that is responsible for providing 
national guidance on the treatment and care of 
people using the NHS in England and Wales. 
One of the responsibilities of NICE is to provide 
guidance to the NHS on the use of selected new 
and established health technologies, based on an 
appraisal of those technologies.
NICE’s single technology appraisal (STA) process 
is specifically designed for the appraisal of a single 
product, device or other technology, with a single 
indication, where most of the relevant evidence 
lies with one manufacturer or sponsor.1 Typically, 
it is used for new pharmaceutical products close 
to launch. The principal evidence for an STA is 
derived from a submission by the manufacturer/
sponsor of the technology. In addition, a report 
reviewing the evidence submission is submitted 
by the evidence review group (ERG), an external 
organisation independent of NICE. This paper 
presents a summary of the ERG report2 for the 
STA entitled ‘Azacitidine (aza) for the treatment 
of myelodysplastic syndrome (MDS), chronic 
myelomonocytic leukaemia (CMML) and acute 
myeloid leukaemia (AML)’.
Description of the underlying 
health problem
The following is taken from the NICE scope for 
this STA.
The MDSs are a diverse group of haematological 
disorders in which the bone marrow functions 
abnormally and insufficient numbers of mature 
blood cells are produced. Red blood cells (RBCs), 
white blood cells and platelets may all be affected 
by MDS, resulting in life threatening disease, 
with anaemia and increased risk of bleeding and 
infections. MDS affects patients’ quality of life 
owing to debilitating symptoms such as fatigue 
and dyspnoea, treatment regimens involving 
hospitalisation with intravenous drug infusions 
and blood transfusions, and complications such as 
severe infections.
Myelodysplastic syndromes are subdivided using 
the International Prognostic Scoring System (IPSS), 
and the French–American–British (FAB) and 
World Health Organization (WHO) classification 
systems. Based on the proportion of leukaemic 
cells (or ‘blasts’), the presence of chromosome 7 
abnormalities and the presence of blood cytopenia, 
the IPSS classifies outcome as either low-risk, 
intermediate-I risk, intermediate-II risk or high-
risk. It is estimated that higher risk MDS subgroups 
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(intermediate-II and high-risk) form approximately 
22% and 7% of the MDS population, respectively. 
The FAB system divides MDS into five subgroups, 
including CMML, which is characterised by high 
numbers of white blood cells in the blood and 
bone marrow. The WHO system, which divides 
MDS into eight subgroups, does not class CMML 
as a type of MDS, but rather within a new category 
of myelodysplastic–myeloproliferative overlap 
syndromes.
Myelodysplastic syndromes are associated with an 
increased risk of transformation to AML. AML is a 
progressive form of MDS characterised by rapidly 
growing cancer of the blood and bone marrow. 
Around 30% of patients with MDS will progress to 
AML.
There were 1993 people newly diagnosed with 
MDS in England in 2004, with over 90% of patients 
aged over 60 years at the time of diagnosis. 
Median survival of patients with MDS is around 
20 months, but can be less than 6 months for 
high-risk subgroups. Establishing the presence of 
chromosome 7 abnormalities is important as this is 
associated with rapid progression to AML.
The mainstay of treatment for MDS is best 
supportive care (BSC) (transfusions, growth 
factors, antibiotics) to control the symptoms of 
bone marrow failure, and low-dose standard 
chemotherapy for some patients. Stem cell 
transplant is not an option for the majority of 
patients as the patient’s age and/or comorbidities 
usually precludes this treatment option.
Scope of the ERG report
The scope for this STA was to address the clinical 
effectiveness and cost-effectiveness of aza relative 
to CCR, particularly BSC, low-dose chemotherapy 
(LDC) and standard-dose chemotherapy (SDC) 
in patients with higher risk MDS, CMML and 
AML with 20–30% blasts. The patient outcomes 
governing relative effectiveness and cost-
effectiveness were defined as: overall survival, time- 
to-progression (TTP) to AML, adverse events and 
health-related quality of life (HRQoL).
The marketing authorisation indicates the dose 
and route of aza to be 75 mg/m2 subcutaneously 
daily for 7 days followed by a rest period of 21 days 
(28-day treatment cycle). It is recommended that 
patients be treated for a minimum of six cycles, 
continuing for as long as the patient continues to 
benefit or until disease progression. The unit cost 
of aza is £321/100 mg.
The key source of evidence on clinical effectiveness 
was an open-label randomised controlled trial 
(RCT) by Fenaux et al.4 referred to as study AZA-
001. It compared aza with CCR in 358 patients 
with higher risk MDS, CMML and AML 20–30% 
blasts. The outcomes reported in AZA-001 included 
overall survival, TTP to AML and adverse events. 
No HRQoL results were reported; however, 
outcomes likely to impact on HRQoL were 
provided (e.g. freedom from transfusion and rates 
of infection requiring intravenous antibiotics).
The manufacturer submitted a de novo economic 
model that was used to estimate the cost per 
quality-adjusted life-year (QALY) gained from aza 
in comparison with BSC, LDC and SDC. HRQoL 
utilities were obtained by mapping with a published 
algorithm to convert European Organisation 
for Research and Treatment of Cancer scores in 
Study CALBG 9221 into European Quality of 
Life-5 Dimensions values. Resource utilisation was 
based on expert opinion gathered from consultant 
haematologists in the UK, and costs were obtained 
from standard sources.
Methods
The ERG report comprised a critical review of the 
evidence for the clinical effectiveness and cost-
effectiveness of the technology based upon the 
manufacturer’s/sponsor’s submission to NICE as 
part of the STA process. This work was undertaken 
in 8 weeks, beginning from 7 June 2009.
Because of the central importance of the AZA-
001 study, it was formally fully appraised by the 
ERG, taking advantage of responses to requests for 
clarification from the manufacturer.
The ERG reran the submission’s search strategies 
after some modifications incorporating minor 
improvements.
The ERG analysed the submitted economic 
model (model 1) and identified a number of 
inconsistencies and errors within the model. 
The manufacturer submitted a revised model for 
analysis by the ERG. Using the issues identified 
in the earlier analysis, the ERG conducted those 
repairs to the revised model that were feasible 
within time constraints.
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The submitted models estimated overall 
survival using log-logistic (baseline) and Weibull 
distribution fits. When estimating uncertainty the 
models assumed a one-to-one and approximately 
linear relationship in these parameters. The ERG 
considered that this likely underestimated variation 
in these parameters and therefore incorporated the 
actual correlation between parameters where made 
available.
The ERG ran an ERG-repaired version of the 
second submitted model encompassing both 
the original two-way comparisons proposed by 
the manufacturer and additionally probabilistic 
sensitivity analyses that, in ERG judgement, might 
more accurately reflect the full range of clinical 
options available for the patient population. Other 
changes were made to the model, but a detailed 
account cannot be provided here.
The ERG extracted overall survival data for all the 
patient subgroups examined in the manufacturer’s 
economic model and prepared Kaplan–Meier plots 
to indicate the inherent uncertainty in the observed 
data.
The ERG explored curve fits to the observed 
overall survival for patient subgroups using a 
greater range of distributions than those provided 
in the manufacturer’s submission.
The ERG tested the face validity of the curve fits 
for overall survival submitted by the manufacturer 
by extrapolating to the base-case time horizon 
(25 years) rather than to the 7.7 years shown in 
the manufacturer’s submission. The ERG also 
compared extrapolations of alternative curve fits.
The ERG extracted data relating to survival in the 
AML state and attempted to replicate the values 
provided in the manufacturer’s submission.
The ERG extracted observed data for TTP to AML 
and compared observed TTP with the modelled 
TTP used in the manufacturer’s economic model.
Results
Summary of submitted 
clinical evidence
The key source of evidence on clinical effectiveness 
was the AZA-001 open-label RCT4 comparing aza 
with CCR in 358 patients with higher risk MDS, 
CMML and AML 20–30% blasts.
The AZA-001 study showed that:
• The median overall survival was 24.5 months 
on aza, compared with 15.0 months in the CCR 
group (p = 0.0001).
• The response rates were low (complete 
remission 17% aza versus 8% CCR).
• The median time to transformation to AML 
was greater in the aza group (17.8 versus 11.5 
months; p < 0.0001).
• Of patients who were RBC transfusion-
dependent at baseline, 45% of those on aza 
became RBC transfusion-independent during 
the treatment period, compared with 11.8% in 
the CCR group (p < 0.0001).
Summary of submitted cost-
effectiveness evidence
The first model submitted by the manufacturer 
provided the following base-case incremental cost-
effectiveness ratio (ICER) values for investigator 
pre-selected subgroups:
aza + BSC versus BSC = £63,295/QALY
aza + LDC versus LDC = £58,837/QALY
aza + SDC versus SDC = £44,523/QALY
The ERG concluded that this model was internally 
incomplete and was not fully executable, and 
apprised the manufacturer of a large number 
of errors and inconsistencies that resulted 
in submission of a second model that was 
accompanied by the base-case ICER values shown 
below:
aza + BSC versus BSC = £51,139/QALY
aza + LDC versus LDC = £47,178/QALY
aza + SDC versus SDC = £34,207/QALY
Commentary on the robustness 
of submitted evidence
Concerning clinical effectiveness, the AZA-001 
study was open to bias, particularly from lack of 
blinding and uncertainty about losses to follow-up. 
In addition there was no direct evidence on impact 
on HRQoL. There is no evidence for differences in 
effects between investigator pre-selected treatment 
groups.
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With regard to cost-effectiveness, the ERG had 
serious concerns regarding the validity of survival 
inputs into the model. However, the overwhelming 
observation concerned the errors in the submitted 
model which were sufficiently severe and 
numerous that the credibility of the estimates of 
cost-effectiveness provided in the manufacturer’s 
submission was completely undermined.
Deficiencies identified in the first submitted model 
included serious coding errors preventing control 
of model assumptions. When these were corrected, 
the model was not functional and did not produce 
results under its base-case assumptions. Other 
issues included: the non-discounting of all cost 
data; minor deficiencies in the discounting of utility 
data; a lack of functionality to reproduce selected 
analyses in the manufacturer’s submission; a large 
amount of redundant material within the model; 
and incorrect or inappropriate characterisation of 
uncertainty in cost, utility and survival estimates.
The manufacturer was apprised of the ERG’s 
concerns regarding the model and submitted a 
second ‘modified’ model.
Although functionality was partially restored and 
discounting was improved in the second model, 
the ERG considered that several serious concerns 
remained unaddressed, the most important 
of these being: failure of the model to reflect 
treatment options available in clinical practice; 
mischaracterisation of the uncertainty in survival 
analyses; lack of face validity regarding base-
case inputs for overall survival; and questionable 
reliability regarding the TTP to AML.
In view of these concerns, the ERG had little 
confidence in the deterministic or probabilistic 
analyses submitted.
The ERG fixed the deficiencies remaining in the 
model as much as was possible within the remit 
of the STA and ran this version in probabilistic 
sensitivity analyses to generate cost-effectiveness 
acceptability frontiers. The ERG considered these 
analyses better reflected the treatment options 
likely to hold in clinical practice than did the two-
way comparisons undertaken in the manufacturer’s 
analyses for those who would otherwise receive 
chemotherapy options (SDC, LDC). The results of 
these exploratory analyses indicated that:
• For SDC-treated patients, of six treatment 
options available, BSC was likely the most cost-
effective option up to a threshold of £51,000/
QALY. Beyond £51,000/QALY, aza + LDC 
became cost-effective.
• For LDC-treated patients, of four options 
available, BSC was again the most cost-effective 
option up to a willingness-to-pay threshold 
of £51,000/QALY (aza + LDC became cost-
effective after £51,000/QALY).
• For BSC-treated patients, aza + BSC became 
cost-effective relative to BSC at a threshold of 
about £52,000/QALY.
The ERG considers these results exploratory 
and considers that they should be viewed with 
caution because of concerns regarding various 
biases relating to the TTP to AML, the uncertainty 
associated with the parameters describing fitted 
curves for overall survival from the trial, the effect 
of age-related non-MDS/AML mortality, and the 
impact of revised Health Resource Group figures.
Conclusions
The AZA-001 study showed that, compared with 
CCR, those MDS patients receiving aza had 
prolonged median survival (by about 9 months), 
had delayed progression to AML, had reduced 
dependence on transfusions and had a small 
improvement in response rate. As an open-label 
design, this study was at risk of bias and there 
was concern regarding losses to follow-up; these 
considerations may indicate some overestimation in 
the survival benefit of aza.
Aza reduces the requirement for transfusion and 
for intravenous antibiotic administration, and the 
claim has been made that ‘azacitidine results in a 
marked improvement in patient well-being’. There 
is no direct research evidence about well-being 
of the patient population of interest in this STA, 
and research on quality of life for MDS patients is 
clearly required.
The economic models submitted for assessment 
were flawed and the cost-effectiveness of aza 
versus CCR was unlikely to be reliably estimated 
using the manufacturer’s submitted models. 
Exploratory analyses using an improved version of 
the manufacturer’s model indicated that in various 
scenarios aza was unlikely to become cost-effective 
relative to competing treatment strategies at a 
willingness to pay of less than £51,000/QALY.
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Given the general paucity of economic modelling 
work in MDS and the limitations of the submitted 
industry model there is an evident need for an 
independent cost-effectiveness analysis of aza in 
MDS.
Note
Because of the extensive inconsistencies and 
errors within the model first submitted by the 
manufacturer the ERG presented a relatively brief 
initial report to NICE indicating that due to model 
inadequacies no reliance could be placed on the 
submitted cost effectiveness estimates. The report 
also encompassed a critical appraisal of the single 
RCT used in the manufacturer’s submission.  This 
report was sent to NICE in line with contractual 
time lines. Subsequently ERG received a second 
economic model submitted by the manufacturer. 
This second model was appraised by the ERG and 
an addendum to the original ERG report was then 
submitted to NICE in time for the first committee 
meeting. This addendum contained a substantial 
critique of the survival analyses underpinning 
the second economic submission together with 
an appraisal of the economic model which 
unfortunately retained several deficiencies.
Summary of NICE guidance 
issued as a result of the STA
At the time of writing, the guidance appraisal 
consultation document5 issued by NICE on 4 
March 2010 states that:
1.1 Azacitidine is not recommended as a 
treatment option for people who have the 
following conditions and are not eligible 
for haemopoietic stem cell transplantation: 
intermediate-2 and high-risk myelodysplastic 
syndromes according to the International 
Prognostic Scoring System (IPSS); chronic 
myelomonocytic leukemia with 10-29% marrow 
blasts without myeloproliferative disorder or 
acute myeloid leukemia with 20-30% blasts and 
multilieage dysplasia, according to the World 
Health Organization classification. 
1.2  People with conditions stated in 1.1 
who are currently receiving azacitidine 
for myelodysplastic syndromes, chronic 
myelomonocytic leukemia or acute myeloid 
leukemia should have the option to continue 
treatment until they and their clinicians 
consider it appropriate to stop.
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Feedback
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The Correspondence Page on the HTA website 
(www.hta.ac.uk) is a convenient way to publish  
your comments. If you prefer, you can send your comments  
to the address below, telling us whether you would like  
us to transfer them to the website.
We look forward to hearing from you.
